US20080064638A1 - Proteins related to schizophrenia and uses thereof - Google Patents
Proteins related to schizophrenia and uses thereof Download PDFInfo
- Publication number
- US20080064638A1 US20080064638A1 US11/893,494 US89349407A US2008064638A1 US 20080064638 A1 US20080064638 A1 US 20080064638A1 US 89349407 A US89349407 A US 89349407A US 2008064638 A1 US2008064638 A1 US 2008064638A1
- Authority
- US
- United States
- Prior art keywords
- pamp
- schizophrenia
- protein
- gene
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 224
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 124
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 68
- 230000035772 mutation Effects 0.000 claims abstract description 60
- 230000000694 effects Effects 0.000 claims abstract description 51
- 108010050254 Presenilins Proteins 0.000 claims abstract description 42
- 102000015499 Presenilins Human genes 0.000 claims abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 241001465754 Metazoa Species 0.000 claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 230000009261 transgenic effect Effects 0.000 claims abstract description 17
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 83
- 230000014509 gene expression Effects 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 31
- 230000003993 interaction Effects 0.000 claims description 30
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 67
- 102000039446 nucleic acids Human genes 0.000 abstract description 61
- 108020004707 nucleic acids Proteins 0.000 abstract description 61
- 238000012216 screening Methods 0.000 abstract description 12
- 238000001415 gene therapy Methods 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000001123 neurodevelopmental effect Effects 0.000 abstract description 3
- 238000011820 transgenic animal model Methods 0.000 abstract description 3
- 230000000877 morphologic effect Effects 0.000 abstract description 2
- 230000003557 neuropsychological effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 138
- 235000018102 proteins Nutrition 0.000 description 116
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 239000013598 vector Substances 0.000 description 47
- 102100022036 Presenilin-2 Human genes 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 description 33
- 229920001184 polypeptide Polymers 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 31
- 102000005650 Notch Receptors Human genes 0.000 description 30
- 108010070047 Notch Receptors Proteins 0.000 description 30
- 210000004899 c-terminal region Anatomy 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 20
- 238000012545 processing Methods 0.000 description 20
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 19
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 18
- 241001529936 Murinae Species 0.000 description 17
- 101500024169 Homo sapiens Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 241000701161 unidentified adenovirus Species 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 208000024827 Alzheimer disease Diseases 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 230000007547 defect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 241001599018 Melanogaster Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- -1 i.e. Proteins 0.000 description 7
- 238000001114 immunoprecipitation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 6
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 6
- 108091060211 Expressed sequence tag Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000012902 Nervous system disease Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000004900 c-terminal fragment Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 230000007466 Aβ secretion Effects 0.000 description 5
- 101100294139 Caenorhabditis elegans aph-2 gene Proteins 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 5
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 101100192145 Homo sapiens PSEN1 gene Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 5
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- 244000105975 Antidesma platyphyllum Species 0.000 description 4
- 102000015735 Beta-catenin Human genes 0.000 description 4
- 108060000903 Beta-catenin Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 102000007474 Multiprotein Complexes Human genes 0.000 description 4
- 108010085220 Multiprotein Complexes Proteins 0.000 description 4
- 230000005913 Notch signaling pathway Effects 0.000 description 4
- 102100022033 Presenilin-1 Human genes 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 235000009424 haa Nutrition 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 230000004777 loss-of-function mutation Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007423 screening assay Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 125000000070 5-oxo-L-proline group Chemical group [H]N1[C@@](C(=O)[*])([H])C([H])([H])C([H])([H])C1=O 0.000 description 3
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 3
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 241000289632 Dasypodidae Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 3
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 201000010829 Spina bifida Diseases 0.000 description 3
- 208000006097 Spinal Dysraphism Diseases 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000021617 central nervous system development Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000004020 intracellular membrane Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 102000046701 nicastrin Human genes 0.000 description 3
- 108700022821 nicastrin Proteins 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102100034213 ATPase family protein 2 homolog Human genes 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 101150089079 PS1 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102220613350 Presenilin-1_D385A_mutation Human genes 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- PEEAINPHPNDNGE-JQWIXIFHSA-N Trp-Asp Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 PEEAINPHPNDNGE-JQWIXIFHSA-N 0.000 description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000015756 familial Alzheimer disease Diseases 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 238000009957 hemming Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 102200058165 rs63750306 Human genes 0.000 description 2
- 102200061470 rs63751416 Human genes 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 108010091193 spermatogenesis associated factor Proteins 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- NSFXVRRBGNORBD-UHFFFAOYSA-N 2h-benzo[f]benzotriazole Chemical compound C1=C2C=CC=CC2=CC2=NNN=C21 NSFXVRRBGNORBD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000034342 Calnexin Human genes 0.000 description 1
- 108010056891 Calnexin Proteins 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100031118 Catenin delta-2 Human genes 0.000 description 1
- 102100038909 Caveolin-2 Human genes 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100192865 Drosophila melanogaster GlyP gene Proteins 0.000 description 1
- 101100290057 Drosophila virilis Mal-B1 gene Proteins 0.000 description 1
- LTLYEAJONXGNFG-DCAQKATOSA-N E64 Chemical compound NC(=N)NCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O LTLYEAJONXGNFG-DCAQKATOSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000922056 Homo sapiens Catenin delta-2 Proteins 0.000 description 1
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 101710162021 Lysosomal protective protein Proteins 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101500024173 Mus musculus Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108091006012 Myc-tagged proteins Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 101150072307 PS gene Proteins 0.000 description 1
- 101150023107 PS2 gene Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000003753 Plakophilins Human genes 0.000 description 1
- 108010057275 Plakophilins Proteins 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
- 101150060955 RAB11A gene Proteins 0.000 description 1
- 241001115903 Raphus cucullatus Species 0.000 description 1
- 102100022873 Ras-related protein Rab-11A Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000713896 Spleen necrosis virus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 101150027402 aph-2 gene Proteins 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
- PHDAZHGCTGTQAS-UHFFFAOYSA-M dimethyl-tetradecyl-(3-trimethoxysilylpropyl)azanium;chloride Chemical group [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CCC[Si](OC)(OC)OC PHDAZHGCTGTQAS-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000028252 learning or memory Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229930182817 methionine Chemical group 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000001683 neutron diffraction Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 210000003458 notochord Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 108091005493 polytopic transmembrane proteins Proteins 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102220049493 rs587784480 Human genes 0.000 description 1
- 102200061602 rs63749806 Human genes 0.000 description 1
- 102200058176 rs63750004 Human genes 0.000 description 1
- 102200061553 rs63750231 Human genes 0.000 description 1
- 102200061555 rs63750231 Human genes 0.000 description 1
- 102200061484 rs63750249 Human genes 0.000 description 1
- 102200061540 rs63750301 Human genes 0.000 description 1
- 102200061543 rs63750543 Human genes 0.000 description 1
- 102200061473 rs63750646 Human genes 0.000 description 1
- 102200061593 rs63750963 Human genes 0.000 description 1
- 102200061547 rs63751139 Human genes 0.000 description 1
- 102200061544 rs63751229 Human genes 0.000 description 1
- 102200061551 rs63751235 Human genes 0.000 description 1
- 102200061526 rs63751420 Human genes 0.000 description 1
- 102200061469 rs661 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 238000010399 three-hybrid screening Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012451 transgenic animal system Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000004474 valine Chemical group 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Definitions
- the present invention relates generally to the field of neurological and physiological dysfunctions associated with neuropsychiatric and neurodevelopmental diseases, especially schizophrenia. More particularly, the invention is concerned with the identification of proteins associated with neuropsychiatric and neurodevelopmental diseases, especially schizophrenia, and relates to methods of diagnosing these diseases, and to methods of screening for candidate compounds which modulate the interaction of a certain protein, specifically Presenilin Associated Membrane Protein (“PAMP”), with presenilin proteins.
- PAMP Presenilin Associated Membrane Protein
- Falkai et al., 2000 provided quantitative data showing that the positioning of neuron (pre-alpha cell) clusters was abnormal in schizophrenia patients, supporting the theory that schizophrenia derives from impaired brain development. Such abnormal neuron positions could, e.g., arise from failures of neuronal migration during fetal development.
- Notch signaling pathway An important pathway implicated in the development of the nervous system, as well as in schizophrenia, is the Notch signaling pathway.
- Notch is a protein receptor for inhibitory signals that shape the pattern of the nervous system, and the localization of Notch signaling is crucial for determining where neural precursor cells arise (Baker, 2000).
- the NOTCH4 locus was highly associated with schizophrenia (Wei and Hemmings, 2000).
- Possible candidate sites conferring susceptibility to schizophrenia included an A-to-G substitution in the promoter region, and the (CTG) n repeat in exon 1, of NOTCH4.
- presenilin 1 encoded by the PS1 gene
- PS2 encoded by the PS2 gene
- PS1 and PS2 genes are involved in the Notch pathway, and form a close functional relationship with Notch during cell fate determination in a variety of species (Selkoe, 2000).
- PS1 and PS2 genes in developmental, apoptotic signaling and in the regulation of proteolytic cleavage of the ⁇ -amyloid precursor protein ( ⁇ APP) (Levitan et al., 1995; Wong et al., 1997; Shen et al., 1997; Wolozin et al., 1996; De Strooper et al., 1998).
- the PS1 gene is associated with migration defects in the central nervous system of PS1 ⁇ / ⁇ mice (Hartmann et al., 1999; Handler et al., 2000).
- ⁇ APP ⁇ APP Ala713Val
- ⁇ APP Ala713Val a mutation in ⁇ APP has been described in one family with a schizophrenia-like illness (Jones et al., 1992), further implicating the PS1/ ⁇ APP/Notch pathways in schizophrenia and related disorders.
- PAMP Presenilin Associated Membrane Protein
- further insights into PAMP and its interaction with PS proteins and other components may lead to new diagnostic and treatment methods for schizophrenia and other related CNS diseases.
- the present invention provides new uses of the PAMP gene, the product of the gene, and mutations and polymorphisms thereof in the study and treatment of a variety of neurological disorders, especially schizophrenia.
- Applicants have surprisingly discovered that PAMP plays a role in the development of schizophrenia.
- the PAMP gene and the product of the PAMP gene therefore present new therapeutic targets for the treatment of a variety of neurological disorders, especially schizophrenia.
- the PAMP gene will be useful for generating animal and cellular models of schizophrenia.
- PAMP nucleic acids, proteins and peptides, antibodies to PAMP, cells transformed with PAMP nucleic acids, and transgenic animals altered with PAMP nucleic acids that possess various utilities are described herein for the diagnosis, therapy and continued investigation of neuropsychiatric and neurodevelopmental disorders, especially schizophrenia.
- mutant PAMP nucleic acids, proteins, or peptides, cells transfected with vectors comprising mutant PAMP nucleic acids, transgenic animals expressing mutant PAMP or peptides thereof, and their use in studying neuropsychiatric and neurodevelopmental disorders, especially schizophrenia, or developing improved diagnostic or therapeutic methods for such disorders, are presented herein.
- the invention provides a method for detecting a mutation in PAMP associated with neuropsychiatric and neurodevelopmental disorders, especially schizophrenia, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having schizophrenia or another neuropsychiatric or neurodevelopmental disorder, and sequencing a gene encoding PAMP from said sample.
- such methods can identify normal human alleles as well as mutant alleles of PAMP genes which are causative of or contribute to neuropsychiatric or neurodevelopmental diseases, especially schizophrenia.
- the invention also provides a method for diagnosing individuals predisposed to or having a neuropsychiatric and/or neurodevelopmental disorder such as schizophrenia, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having such a disorder, and sequencing a gene encoding PAMP from said sample.
- the invention also provides a method for diagnosing individuals predisposed to or having a neuropsychiatric and/or neurodevelopmental disorder such as schizophrenia, comprising obtaining cells that contain nucleic acid encoding PAMP, and under non-pathological conditions, transcribing the nucleic acid, and measuring a level of transcriptional activity of the nucleic acid.
- the invention further provides a method for diagnosing individuals predisposed to or having a neuropsychiatric or neurodevelopmental disorder, especially schizophrenia, comprising obtaining cells from an individual that express nucleic acid encoding PAMP, and measuring PAMP activity.
- PAMP could be isolated from that individual to investigate, for example, whether the PAMP amino acid sequence is similar or different from wild-type PAMP, and/or whether PAMP expression levels differ from typical PAMP levels.
- the activity or abundance of a PAMP substrate may be measured.
- the invention also provides a method for identifying putative agents that affect a neuropsychiatric and/or neurodevelopmental disorder, especially schizophrenia, comprising administering one or more putative agents to a transgenic animal and detecting a change in PAMP activity.
- the invention also provides a method for identifying putative agents that affect a neuropsychiatric and/or neurodevelopmental disorder, especially schizophrenia, comprising adding one or more said agents to the reconstituted system described above, and detecting a change in PAMP activity.
- the invention also provides a method for identifying putative agents that affect a neuropsychiatric and/or neurodevelopmental disorder, especially schizophrenia, comprising adding one or more said agents to the complex described above, and detecting a conformational change in PAMP.
- the invention also provides a method for identifying proteins that interact with PAMP, comprising contacting a substance to the reconstituted system discussed above, and detecting a change in PAMP activity.
- the invention also provides animal and cellular models of schizophrenia or related disorders that comprise a PAMP gene as a therapeutic target for the development of drugs which interact with PAMP, and thus may be useful in the treatment and prevention of schizophrenia or related disorders.
- the invention provides for a method for identifying substances that modulate PAMP activity, comprising contacting a sample containing one or more substances with PAMP, or a PAMP mutant, or functional fragments thereof, and a PAMP substrate, measuring PAMP activity, and determining whether a change in PAMP activity occurs.
- the substance is a PAMP inhibitor.
- the substance stimulates PAMP activity.
- FIGS. 1A and 1B Predicted amino acid sequences for human (SEQ ID NO: 14), mouse (SEQ ID NO: 16), D. melanogaster (SEQ ID NO:18) and C. elegans (SEQ ID NO: 12) PAMP orthologues.
- the PAMP gene and its product, the PAMP protein present new therapeutic targets for the treatment of a variety of neurological disorders, especially schizophrenia.
- Provided herein are also new strategies to create animal and cellular models based on PAMP or PAMP mutants to study schizophrenia and potential treatment strategies.
- the invention also offers the potential for new diagnostic screening methods for schizophrenia, wherein the PAMP gene and PAMP protein are investigated.
- PAMP Presenilin Associated Membrane Protein
- PAMP defects in CNS development, such as defects in neuronal migration, are associated with schizophrenia, and PAMP is linked to this disorder through several lines of evidence, such as (1) the PAMP gene maps to the same location as the schizophrenia susceptibility gene, as described above; (2) PAMP interacts with PS1, which is associated with migration defects in the central nervous system in PS I ⁇ / ⁇ mice (see above); (3) PAMP is involved in the Notch signaling pathway, one gene locus of which (NOTCH4) is implicated in schizophrenia (see above); and (4) a mutation in ⁇ APP is associated with a schizophrenia-like illness (see above). Therefore, PAMP can contribute to the development of schizophrenia via several routes, e.g., through mutations and/or polymorphisms in PAMP, variations in its expression levels, and defects in its interactions with other components in neural development and/or migration.
- PAMP means a native or mutant full-length protein, or fragments thereof, that interacts with the PAMP-interacting domain of a presenilin protein.
- PAMP is also known under the name “Nicastrin”. Human, murine, D. melanogaster and C. elegans orthologues are provided.
- PAMP ProteinBank Accession No. Q92542; SEQ ID NO: 14
- the nucleotide sequence (SEQ ID NO: 13) of human PAMP predicts that the gene encodes a Type 1 transmembrane protein of 709 amino acids (SEQ ID NO: 14), the protein having a short hydrophilic C-terminus ( ⁇ 20 residues), a hydrophobic transmembrane domain (15-20 residues), and a longer N-terminal hydrophilic domain which contains several potentially functional sequence motifs as listed below in Table 1.
- the PAMP sequence also contains a Trp-Asp (WD) repeat (residue 226), at least one “DTG” motif (residues 91-93) present in eukaryotic aspartyl proteases, as well as several “TDTA/DTAE” motifs (residues 480-482, 504-506) present in viral aspartyl proteases.
- WD Trp-Asp
- TDTA/DTAE motifs
- cysteine residues in the N-terminal hydrophilic domain Cys 195 , Cys 213 , Cys 230 , and Cys 248 in human PAMP having a periodocity of 16-17 residues, which may form a functional domain (e.g.
- N-asparaginyl glycosylation 45 N-asparaginyl glycosylation 45 (NKTA), 55 (NATH), 187 (NETK), 200 (NLSQ), 204 (NGSA), 264 (NTTG), 387 (NESV), 417 (NQSQ), 435 (NISG), 464 (NVSY), 506 (NFSD), 530 (NNSW), 562 (NTTY), 573 (NLTG), 580 (NLTR), 612 (NETD) Glycosaminoglycan attachment 404 (SGAG) Myristolation 5 (GGGSGA), 29 (GLCRGN), 61 (GCQSSI), 120 (GLAVSL), 146 (GVYSNS), 167 (GNGLAY), 205 (GSAPTF), 294 (GAESAV), 438 (GVVLAD), 446 (GAFHNK), 504 (GTNFSD), 576 (GTVVNL) Phosphorylation sites for cAMP- and 232 (RRSS) cGMP-dependent
- the invention is further based on the identification of conserved functional domains, based on comparison and evaluation of the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), D. melanogaster (SEQ ID NO: 18), and C. elegans (SEQ ID NO: 12) orthologues of PAMP.
- PAMP can be characterized by the presence of conserved structural features, relative to orthologues from D. melanogaster and C. elegans .
- One domain has chemical similarities to cyclic nucleotide binding domains of other proteins, and may have some regulatory role on a potential complex formed between PS1:PAMP and the C-terminal fragment of ⁇ APP, derived either from ⁇ - or ⁇ -secretase. These putative functional domains are sites for therapeutic target development by deploying drugs which might interact with these sites to modulate ⁇ APP processing via this complex.
- PAMP also refers to functionally active fragments of the protein.
- Such fragments include, but are not limited to, peptides that contain an epitope, e.g., as determined by conventional algorithms such as hydrophilicity/hydrophobicity analysis for antibody epitopes, and amphipathicity or consensus algorithms for T cell epitopes (Spouge et al., 1987; Margalit et al., 1987; Rothbard, 1986; Rothbard and Taylor, 1988).
- a functionally active fragment of PAMP is a conserved domain, relative to the D. melanogaster and C. elegans orthologues.
- a specific functionally active fragment of PAMP is a fragment that interacts with PS1 or PS2, or both.
- PAMP also encompasses naturally occurring variants, including other mammalian PAMPs (readily identified, as shown herein for murine PAMP, based on the presence of the structural features set forth above), allelic variants of PAMP from other human sources (including variants containing polymorphisms that are predictive of disease propensity or of response to pharmacological agents), and mutant forms of PAMP or PAMP genes that are associated with neurological diseases and disorders (such as spina bifida), particularly neuropsychiatric disorders (such as schizophrenia). Also included are artificial PAMP mutants created by standard techniques such as site directed mutagenesis or chemical synthesis.
- a PAMP “substrate” may be a polypeptide or protein, or any other type of compound, with which PAMP interacts physiologically.
- PAMP substrates include PS1, PS2, and ⁇ APP.
- a PAMP “ligand” may be a polypeptide, protein, lipid, carbohydrate, vitamin, mineral, amino acid, or any other type of compound which binds to PAMP Hypothetically, PAMP may function as a receptor which modulates PS1/PS2/ ⁇ APP processing in response to signal (ligand) dependent interactions with PAMP.
- Neuropsychiatric disorders or “diseases” include recognized variants of overt schizophrenia (e.g., paranoid, catatonic), other related psychoses such as schizoaffective, schizotypal, schizophreniform and delusional disorders, and personality disorders such as schizoid personality disorder, schizotypal personality disorder, and paranoid personality disorder (see definitions in DSM-III-R, Diagnostic and Statistical Manual of the American Psychiatric Association; and Flaum et al., 1997).
- schizophrenia e.g., paranoid, catatonic
- other related psychoses such as schizoaffective, schizotypal, schizophreniform and delusional disorders
- personality disorders such as schizoid personality disorder, schizotypal personality disorder, and paranoid personality disorder (see definitions in DSM-III-R, Diagnostic and Statistical Manual of the American Psychiatric Association; and Flaum et al., 1997).
- PAMP nucleic acid molecule
- normal text e.g., PAMP
- the term “about” or “approximately” means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.
- the term about means within an order of magnitude of a given value, preferably within a multiple of about 5-fold, and more preferably within a factor of about 2-fold of a given value.
- an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment.
- an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome.
- the isolated nucleic acid lacks one or more introns.
- Isolated nucleic acid molecules can be inserted into plasmids, cosmids, artificial chromosomes, and the like.
- a recombinant nucleic acid is an isolated nucleic acid.
- An isolated protein may be associated with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane associated protein.
- An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism.
- An isolated material may be, but need not be, purified.
- purified refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, i.e., contaminants.
- a purified protein is preferably substantially free of other proteins or nucleic acids with which it is associated in a cell;
- a purified nucleic acid molecule is preferably substantially free of proteins or other unrelated nucleic acid molecules with which it can be found within a cell.
- the term “substantially free” is used operationally, in the context of analytical testing of the material.
- purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
- host cell means any cell of any organism that is selected, modified, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression by the cell of a gene, a DNA or RNA sequence, a protein or an enzyme. Host cells can further be used for screening or functional assays, as described infra.
- a host cell has been “transfected” by exogenous or heterologous DNA when such DNA has been introduced inside the cell.
- a cell has been “transformed” by exogenous or heterologous DNA when the transfected DNA is expressed and effects a function or phenotype on the cell in which it is expressed.
- expression system means a host cell transformed by a compatible expression vector and cultured under suitable conditions e.g. for the expression of a protein coded for by foreign DNA carried by the vector and introduced to the host cell.
- Proteins and polypeptides can be made in the host cell by expression of recombinant DNA.
- polypeptide refers to an amino acid-based polymer, which can be encoded by a nucleic acid or prepared synthetically. Polypeptides can be proteins, protein fragments, chimeric proteins, etc.
- protein refers to a polypeptide expressed endogenously in a cell, e.g., the naturally occurring form (or forms) of the amino acid-based polymer.
- a “coding sequence” or a sequence “encoding” an expression product, such as a RNA, polypeptide, protein, or enzyme is a nucleotide sequence that, when expressed, results in the production of that RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme.
- a coding sequence for a protein may include a start codon (usually ATG) and a stop codon.
- the coding sequences herein may be flanked by natural regulatory (expression control) sequences, or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5′- and 3′-non-coding regions, and the like.
- the nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications.
- gene also called a “structural gene” means a DNA sequence that codes for or corresponds to a particular sequence of ribonucleic acids or amino acids which comprise all or part of one or more proteins, and may or may not include regulatory DNA sequences, such as promoter sequences, which determine for example the conditions under which the gene is expressed.
- a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3′ direction) coding sequence.
- the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
- a coding sequence is “under the control” or “operatively associated with” transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which then may be trans-RNA spliced (if it contains introns) and translated into the protein encoded by the coding sequence.
- express and “expression” mean allowing or causing the information in a gene or DNA sequence to become manifest, for example producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence.
- a DNA sequence is expressed in or by a cell to form an “expression product” such as a protein.
- the expression product itself e.g. the resulting protein, may also be said to be “expressed” by the cell.
- transfection means the introduction of a foreign nucleic acid into a cell.
- transformation means the introduction of a “foreign” (i.e. extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence.
- the introduced gene or sequence may also be called a “cloned”, “foreign”, or “heterologous” gene or sequence, and may include regulatory or control sequences used by a cell's genetic machinery.
- the gene or sequence may include nonfunctional sequences or sequences with no known function.
- a host cell that receives and expresses introduced DNA or RNA has been “transformed” and is a “transformant” or a “clone.”
- the DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different genus or species.
- vector means the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence.
- Vectors include plasmids, phages, viruses, etc.
- a “cassette” refers to a DNA coding sequence or segment of DNA that codes for an expression product that can be inserted into a vector at defined restriction sites. The cassette restriction sites are designed to ensure insertion of the cassette in the proper reading frame. Generally, foreign DNA is inserted at one or more restriction sites of the vector DNA, and then is carried by the vector into a host cell along with the transmissible vector DNA.
- a segment or sequence of DNA having inserted or added DNA can also be called a “DNA construct.”
- Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes.
- a “knockout mammal” is a mammal (e.g., mouse) that contains within its genome a specific gene that has been inactivated by the method of gene targeting (see, e.g., U.S. Pat. No. 5,777,195 and No. 5,616,491).
- a knockout mammal includes both a heterozygote knockout (i.e., one defective allele and one wild-type allele) and a homozygous mutant.
- Preparation of a knockout mammal requires first introducing a nucleic acid construct that will be used to suppress expression of a particular gene into an undifferentiated cell type termed an embryonic stem cell. This cell is then injected into a mammalian embryo.
- a mammalian embryo with an integrated cell is then implanted into a foster mother for the duration of gestation.
- Zhou, et al., 1995 describes PPCA knock-out mice.
- Knockout mice can be used to study defects in neurological development or neurodegenerative diseases. Disease phenotypes that develop can provide a platform for further drug discovery.
- knockout refers to partial or complete suppression of the expression of at least a portion of a protein encoded by an endogenous DNA sequence in a cell.
- knockout construct refers to a nucleic acid sequence that is designed to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell.
- the nucleic acid sequence used as the knockout construct is typically comprised of (1) DNA from some portion of the gene (exon sequence, intron sequence, and/or promoter sequence) to be suppressed and (2) a marker sequence used to detect the presence of the knockout construct in the cell.
- the knockout construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to prevent or interrupt transcription of the native DNA sequence.
- Such insertion usually occurs by homologous recombination (i.e., regions of the knockout construct that are homologous to endogenous DNA sequences hybridize to each other when the knockout construct is inserted into the cell and recombine so that the knockout construct is incorporated into the corresponding position of the endogenous DNA).
- the knockout construct nucleic acid sequence may comprise 1) a full or partial sequence of one or more exons and/or introns of the gene to be suppressed, 2) a full or partial promoter sequence of the gene to be suppressed, or 3) combinations thereof.
- the knockout construct is inserted into an embryonic stem cell (ES cell) and is integrated into the ES cell genomic DNA, usually by the process of homologous recombination. This ES cell is then injected into, and integrates with, the developing embryo.
- ES cell embryonic stem cell
- the DNA will be at least about 1 kilobase (kb) in length and preferably 3-4 kb in length, thereby providing sufficient complementary sequence for recombination when the knockout construct is introduced into the genomic DNA of the ES cell.
- a “knock-in” mammal is a mammal in which an endogenous gene is substituted with a heterologous gene or a modified variant of the endogenous gene (Roemer et al., 1991).
- the heterologous gene is “knocked-in” to a locus of interest, for example into a gene that is the subject of evaluation of expression or function, thereby linking the heterologous gene expression to transcription from the appropriate promoter (in which case the gene may be a reporter gene; see Elefanty et al., 1998). This can be achieved by homologous recombination, transposon (Westphal and Leder, 1997), using mutant recombination sites (Araki et al., 1997) or PCR (Zhang and Henderson, 1998).
- disruption of the gene and “gene disruption” refer to insertion of a nucleic acid sequence into one region of the native DNA sequence (usually one or more exons) and/or the promoter region of a gene so as to decrease or prevent expression of that gene in the cell as compared to the wild-type or naturally occurring sequence of the gene.
- a nucleic acid construct can be prepared containing a DNA sequence encoding an antibiotic resistance gene which is inserted into the DNA sequence that is complementary to the DNA sequence (promoter and/or coding region) to be disrupted. When this nucleic acid construct is then transfected into a cell, the construct will integrate into the genomic DNA. Thus, some progeny of the cell will no longer express the gene, or will express it at a decreased level, as the DNA is now disrupted by the antibiotic resistance gene.
- heterologous refers to a combination of elements not naturally occurring.
- heterologous DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell.
- the heterologous DNA includes a gene foreign to the cell.
- a heterologous expression regulatory element is a such an element operatively associated with a different gene than the one it is operatively associated with in nature.
- an gene is heterologous to the recombinant vector DNA in which it is inserted for cloning or expression, and it is heterologous to a host cell containing such a vector, in which it is expressed, e.g., a CHO cell.
- mutant and “mutation” mean any detectable change in genetic material, e.g. DNA, or any process, mechanism, or result of such a change. This includes gene mutations, in which the structure (e.g., DNA sequence) of a gene is altered, any gene or DNA arising from any mutation process, and any expression product (e.g., protein) expressed by a modified gene or DNA sequence.
- variant may also be used to indicate a modified or altered gene, DNA sequence, enzyme, cell, etc., i.e., any kind of mutant.
- Sequence-conservative variants of a polynucleotide sequence are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position.
- “Function-conservative variants” are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like).
- Amino acids with similar properties are well known in the art. For example, arginine, histidine and lysine are hydrophilic-basic amino acids and may be interchangeable. Similarly, isoleucine, a hydrophobic amino acid, may be replaced with leucine, methionine or valine.
- Amino acids other than those indicated as conserved may differ in a protein or enzyme so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm.
- a “function-conservative variant” also includes a polypeptide or enzyme which has at least 60% amino acid identity as determined by BLAST (Altschul, et al., 1990) or FASTA algorithms, preferably at least 75%, most preferably at least 85%, and even more preferably at least 90%, and which has the same or substantially similar properties or functions as the native or parent protein or enzyme to which it is compared.
- orthologous proteins typically have similar functions in different species, and can also be substantially homologous.
- homologous in all its grammatical forms and spelling variations refers to the relationship between proteins that possess a “common evolutionary origin,” including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck et al., 1987). Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity or the presence of specific residues or motifs. Motif analysis can be performed using, for example, the program BLOCKS (blocks.fhcrc.org on the World-Wide Web).
- sequence similarity in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin (see Reeck et al., supra).
- sequence similarity when modified with an adverb such as “highly,” may refer to sequence similarity and may or may not relate to a common evolutionary origin.
- two DNA sequences are “substantially homologous” or “substantially similar” when at least about 80%, and most preferably at least about 90 or 95% of the nucleotides match over the defined length of the DNA sequences, as determined by sequence comparison algorithms, such as BLAST, FASTA, DNA Strider, etc. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system.
- two amino acid sequences are “substantially homologous” or “substantially similar” when greater than 80% of the amino acids are identical, or greater than about 90% are similar (functionally identical).
- the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wis.) pileup program, ProteinPredict (dodo.cmpc.columbia.edu/predictprotein on the World-Wide Web), or any of the programs described above (BLAST, FASTA, etc.).
- a nucleic acid molecule is “hybridizable” to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strenght (see Sambrook et al., supra).
- the conditions of temperature and ionic strength determine the “stringency” of the hybridization.
- low stringency hybridization conditions corresponding to a T m (melting temperature) of 55° C.
- Moderate stringency hybridization conditions correspond to a higher T m and high stringency hybridization conditions correspond to the highest T m .
- Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible.
- the appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T m for hybrids of nucleic acids having those sequences.
- the relative stability (corresponding to higher T m ) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.
- a minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.
- antisense nucleic acids including ribozymes
- An “antisense nucleic acid” is a single stranded nucleic acid molecule which, on hybridizing under cytoplasmic conditions with complementary bases in an RNA or DNA molecule, inhibits the latter's role. If the RNA is a messenger RNA transcript, the antisense nucleic acid is a counter transcript or mRNA-interfering complementary nucleic acid. As presently used, “antisense” broadly includes RNA-RNA interactions, RNA-DNA interactions, ribozymes and RNase-H mediated arrest.
- Antisense nucleic acid molecules can be encoded by a recombinant gene for expression in a cell (e.g., U.S. Pat. No. 5,814,500; U.S. Pat. No. 5,811,234), or alternatively they can be prepared synthetically (e.g., U.S. Pat. No. 5,780,607).
- oligonucleotide refers to a nucleic acid, generally of at least 10, preferably at least 15, and more preferably at least 20 nucleotides, preferably no more than 100 nucleotides, that is hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene, mRNA, cDNA, or other nucleic acid of interest. Oligonucleotides can be labeled, e.g., with 32 P-nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated.
- a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid.
- oligonucleotides (one or both of which may be labeled) can be used as PCR primers, e.g. for cloning full length or a fragment of a protein or polypeptide.
- an oligonucleotide of the invention can form a triple helix with a nucleic acid (genomic DNA or mRNA) encoding a protein or polypeptide.
- oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer.
- oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc.
- the oligonucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly.
- Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.
- synthetic oligonucleotides envisioned for this invention include oligonucleotides that contain phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl, or cycloalkl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages.
- U.S. Pat. No. 5,637,684 describes phosphoramidate and phosphorothioamidate oligomeric compounds.
- oligonucleotides having morpholino backbone structures U.S. Pat. No. 5,034,506.
- the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al., 1991).
- oligonucleotides may contain substituted sugar moieties comprising one of the following at the 2′ position: OH, SH, SCH 3 , F, OCN, O(CH 2 ) n NH 2 or O(CH 2 ) n CH 3 where n is from 1 to about 10; C 1 to C 10 lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF 3 ; OCF 3 ; O—; S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH 3 ; SO 2 CH 3 ; ONO 2 ; NO 2 ; N 3 ; NH 2 ; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; a fluorescein moiety; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligon
- Oligonucleotides may also have sugar mimetics such as cyclobutyls or other carbocyclics in place of the pentofuranosyl group.
- Nucleotide units having nucleosides other than adenosine, cytidine, guanosine, thymidine and uridine, such as inosine, may be used in an oligonucleotide molecule.
- the presenilin genes encode homologous polytopic transmembrane proteins that are expressed at low levels in intracellular membranes including the nuclear envelope, the endoplasmic reticulum, the Golgi apparatus and some as yet uncharacterized intracytoplasmic vesicles in many different cell types including neuronal and non-neuronal cells (see U.S. application Ser. No. 08/431,048, filed Apr. 28, 1995; 08/496,841, filed Jun. 28, 1995; and 08/509,359, filed Jul. 31, 1995; PCT Publication No. WO 96/34099, and U.S. Pat. Nos.
- TM transmembrane
- the presenilins contain between six and eight transmembrane (TM) domains organized such that the N-terminus, the C-terminus, and a large hydrophilic loop following the sixth TM domain are located in the cytoplasm or nucleoplasm, while the hydrophilic loop between TM1 and TM2 is located within the lumen of membranous intracellular organelles (Doan et al., 1996; De Strooper et al., 1997; Lehmann et al., 1997).
- TM transmembrane
- Proteins that interact with the presenilins i.e., PS-interacting-protein elude PAMP, the S5a subunit of the 26S proteasome (GenBank; Accession No. U51007), Rab11 (GenBank; Accession Nos. X56740 and X53143), retinoid X receptor B, also known as nuclear receptor co-regulator or MHC (GenBank Accession Nos. M84820, and X63522), GT24 (GenBank Accession No. U81004), ⁇ -catenin (Zhou et al., 1997, and Yu et al., supra) as well as armadillo proteins.
- PS1 binding proteins are described in Applicants' copending commonly assigned U.S.
- PS1 and PS2 interact specifically with at least two members of the armadillo family of proteins; neuronal plakophilin-related armadillo protein (Paffenholtz et al., 1997; Paffenholtz et al., 1999; Zhou et al. (2), 1997) and ⁇ -catenin, that are expressed in both embryonic and post-natal tissues. Moreover, the domains of PS1 and PS2 that interact with these proteins have been identified. Mutations in PS1 and PS2 affect the translocation of ⁇ -catenin into the nucleus of both native cells and cells transfected with a mutant PS gene. These interactions and effects are described in detail in co-pending commonly assigned U.S. application Ser. No. 09/227,725, filed Jan. 8, 1999, the disclosure of which is incorporated herein by reference.
- the methods of the present invention are not limited to mutant presenilins wherein the PAMP-interacting domain is mutated relative to the wild-type protein.
- PS1 e.g., M146L
- interacting domain loop
- these mutations probably disturb the presenilin armadillo interactions by altering the function of a high MW complex which contains, e.g., the presenilin and armadillo proteins, as described in Yu et al., 1998.
- hPS1 and PS2 (hPS2) sequences reveals that these pathogenic mutations are in regions of the PS1 protein which are conserved in the PS2 protein. Therefore, corresponding mutations in corresponding regions of PS2 may also be expected to be pathogenic and are useful in the methods described herein.
- PS1 and PS2 genes are described in Applicants' co-pending U.S. application Ser. No. 08/888,077, filed Jul. 3, 1997, and incorporated herein by reference.
- PS1 mutations include I143T, M146L, L171P, F177S, A260V, C263R, P264L, P267S, E280A, E280G, A285V, L286V, A291-319, L322V, G384A, L392V, C410Y and I439V.
- PS2 mutations include N141I, M239V and I420T.
- PAMP mutants may cause biochemical changes similar to those affecting the onset or progression of schizophrenia. Therefore, artificial PAMP mutations can potentially be used to generate cellular and other model systems to design treatments and preventive strategies for schizophrenia and related disorders. Such mutations may also be used for evaluating whether PAMP is involved in the pathogenesis of schizophrenia. Since the amyloid- ⁇ (A ⁇ ) inducing mutations are found in amino acid residues of a soluble (non-membrane spanning) domain of PAMP, analysis of the normal structure of this domain and the effects of these and other nearby mutations on the structure of this domain (and the other domains of PAMP) provide information for the design of specific molecular therapeutics.
- a ⁇ amyloid- ⁇
- modifications of the sequences encoding the polypeptides described herein may be readily accomplished by standard techniques such as chemical syntheses and site-directed mutagenesis. See Gillman et al., 1979; Roberts et al., 1987; and Innis, 1990. Most modifications are evaluated by routine screening via an assay designed to select for the desired property.
- PAMP polypeptides produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins and PAMP mutants may be used as an immunogen to generate antibodies that recognize the PAMP polypeptide.
- antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
- Such an antibody is preferably specific for human PAMP, PAMP originating from other species, or for post-translationally modified (e.g. phosphorylated, glycosylated) PAMP.
- PAMP polypeptide or derivative or analog thereof various procedures known in the art may be used for the production of polyclonal antibodies to PAMP polypeptide or derivative or analog thereof.
- various host animals can be immunized by injection with the PAMP polypeptide, or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc.
- the PAMP polypeptide or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH).
- BSA bovine serum albumin
- KLH keyhole limpet hemocyanin
- adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum .
- Antisera may be collected at a chosen time point after immunization, and purified as desired.
- any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Köhler and Milstein, 1975, as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983; Cote et al., 1983), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985). Production of human antibodies by CDR grafting is described in U.S. Pat. Nos.
- monoclonal antibodies can be produced in germ-free animals (International Patent Publication No. WO 89/12690, published 28 Dec. 1989).
- chimeric antibodies In fact, according to the invention, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984); Neuberger et al., 1984; Takeda et al., 1985) by splicing the genes from a mouse antibody molecule specific for an PAMP polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.
- Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described infra), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.
- Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques.
- such fragments include but are not limited to: the F(ab′) 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab′ fragments which can be generated by reducing the disulfide bridges of the F(ab′) 2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
- screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), “sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.
- radioimmunoassay e.g., ELISA (enzyme-linked immunosorbent assay), “sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoa
- antibody binding is detected by detecting a label on the primary antibody.
- the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody.
- the secondary antibody is labeled.
- Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of an PAMP polypeptide, one may assay generated hybridomas for a product which binds to an PAMP polypeptide fragment containing such epitope. For selection of an antibody specific to an PAMP polypeptide from a particular species of animal, one can select on the basis of positive binding with PAMP polypeptide expressed by or isolated from cells of that species of animal.
- the foregoing antibodies can be used in methods known in the art relating to the localization and activity of the PAMP polypeptide, e.g., for Western blotting, imaging PAMP polypeptide in situ, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned above or known in the art.
- Such antibodies can be used to identify proteins that interact with PAMP, and to detect conformational or structural changes in PAMP.
- antibodies that agonize or antagonize the activity of PAMP polypeptide can be generated. They can also be used to regulate or inhibit PAMP activity intracellular, i.e., the invention contemplates an intracellular antibody (intrabody), e.g., single chain Fv antibodies (see generally, Chen, 1997; Spitz et al., 1996; Indolfi et al., 1996; Kijima et al., 1995).
- intracellular antibody e.g., single chain Fv antibodies
- the nucleotide sequence and the protein sequence and the putative biological activity of PAMP or PAMP mutants can all be used for the purposes of diagnosis of individuals who are at-risk for, or who actually have, a variety of neurodegenerative diseases (including Alzheimer's disease, Lewy body variant, Parkinson's disease-dementia complex, amyotrophic lateral sclerosis etc.), neuropsychiatric diseases (schizophrenia, depression, mild cognitive impairment, benign senescent forgetfulness, age-associated memory loss, etc.), neurodevelopmental disorders associated with defects in intracellular signal transduction mediated by factors such as Notch, Delta, Wingless, etc., and neoplasms (e.g., bowel cancer, etc.) associated with abnormalities of PS1/PAMP/PS2 mediated regulation of cell death pathways.
- neurodegenerative diseases including Alzheimer's disease, Lewy body variant, Parkinson's disease-dementia complex, amyotrophic lateral sclerosis etc.
- neuropsychiatric diseases schizophrenia
- diagnostic entities can be used by searching for alterations in: the nucleotide sequence of PAMP; in the transcriptional activity of PAMP; in the protein level as monitored by immunological means (e.g. ELISA and Western blots); in the amino acid sequence (as ascertained by Western blotting, amino acid sequence analysis, mass spectroscopy); and/or in the biological activity of the PAMP protein as measured by either in vivo methods (e.g., monitoring ⁇ APP processing and the production of amyloid- ⁇ peptide (A ⁇ ), or other suitable protein substrates for PAMP including Notch, etc.), or by in vitro assays (using either whole cell or cell-free assays to measure processing of suitable substrate including ⁇ APP or parts thereof, and other proteins such as Notch). Any of these assays can also be performed in a transgenic animal model as well, e.g., to measure the effect of a drug or a mutation or overexpression of a different gene in vivo.
- immunological means e.g. EL
- Identification and isolation of PAMP provides for development of screening assays, particularly for high throughput screening of molecules that up- or down-regulate the activity of PAMP, e.g., by permitting expression of PAMP in quantities greater than can be isolated from natural sources, or in indicator cells that are specially engineered to indicate the activity of PAMP expressed after transfection or transformation of the cells.
- Any screening technique known in the art can be used to screen for PAMP agonists or antagonists.
- the present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to and agonize or antagonize the activity of PAMP in vivo.
- natural products libraries can be screened using assays of the invention for molecules that agonize or antagonize PAMP activity.
- Another approach uses recombinant bacteriophage to produce large libraries. Using the “phage method” (Scott and Smith, 1990; Cwirla, et al, 1990; Devlin et al., 1990), very large libraries can be constructed (10 6 -10 8 chemical entities).
- a second approach uses primarily chemical methods, of which the Geysen method (Geysen et al., 1986; Geysen et al., 1987; and the method of Fodor et al. (1991) are examples. Furka et al., 1988, Furka, 1991, Houghton (U.S. Pat. No. 4,631,211) and Rutter et al. (U.S. Pat. No. 5,010,175) describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.
- synthetic libraries (Needels et al., 1993; Ohlmeyer et al., 1993; Lam et al., WO 92/00252; Kocis et al., WO 9428028) and the like can be used to screen for PAMP ligands according to the present invention.
- the PAMP protein sequence (including parts thereof) can be used to deduce the structural organization and topology of PAMP through the use of a variety of techniques including CD spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and molecular modeling. Sequences for PAMP or PAMP mutants can also be used to identify proteins which interact with PAMP either in concert with PS1 and PS2, or independently, using a variety of methods including co-immunoprecipitation, yeast two hybrid interaction trap assays, yeast three hybrid interaction trap assays, chemical cross-linking and co-precipitation studies, etc. These and other methods are described more fully in co-pending and commonly assigned U.S. application Ser. No. 08/888,077, filed Jul. 3, 1997, and 09/227,725, filed Jan. 8, 1999, both of which are incorporated herein by reference. Identification of these interacting partners will then lead to their use to further delineate the biochemical pathways leading to the above-mentioned diseases.
- the structure and topology of these domains can all be used as a basis for the rational design of pharmaceuticals (small molecule conventional drugs or novel carbohydrate, lipid, DNA/RNA or protein-based high molecular weight biological compounds) to modulate (increase or decrease) the activity of PAMP and/or the PAMP PS1/PS2 complex, and/or the activity of the PAMP/other protein complexes.
- pharmaceuticals small molecule conventional drugs or novel carbohydrate, lipid, DNA/RNA or protein-based high molecular weight biological compounds
- spectroscopic data like nuclear magnetic resonance, circular dichroism, and other physical-chemical structural data, or crystallographic data, or both.
- Drug candidates generated using a rational drug design program can then be applied for the treatment and/or prevention of the above-mentioned diseases, and can be administered through a variety of means including: as conventional small molecules through enteral or parenteral routes; via inclusion in liposome vehicles; through infusion in pumps inserted into various organs (e.g., via Omaya pumps inserted into the cerebral ventricles); via the transplantation of genetically-modified cells expressing recombinant genes; or via the use of biological vectors (e.g., retrovirus, adenovirus, adeno-associated virus, Lentivirus, or herpes simplex virus-based vectors) which allow targeted expression of appropriately modified gene products in selected cell types.
- biological vectors e.g., retrovirus, adenovirus, adeno-associated virus, Lentivirus, or herpes simplex virus-based vectors
- the recombinant proteins described above may be the wild-type PAMP, a genetically-modified PAMP, a wild-type PS1/PS2, a genetically-modified PS1/PS2, or a specially-designed protein or peptide which is designed to interact with either the functional domains of PAMP (or the PAMP/PS 1/PS2/other protein complex) or to interact with the domains which modulate the activity of the functional domains of PAMP.
- the PAMP nucleotide sequence can be used to make cell-free systems, transfected cell lines, and animal models (invertebrate or vertebrate) of the neurodegenerative and other diseases outlined above. These animal and cell models may involve over-expression of all or part of PAMP or PAMP mutants, e.g., as mini-gene cDNA transgene constructs under the regulation of suitable promoter elements carried in vectors such as cos-Tet for transgenic mice and pcDNA (Invitrogen, California) in transfected cell lines.
- Animal and cellular models can also be generated by via homologous recombination mediated targeting of the endogenous gene to create artificially mutant sequences (knock-in gene targeting); or loss of function mutations (knock-out gene targeting); by translocation of P-elements; and by chemical mutagenesis.
- Animal, cellular and cell-free model systems can be used for a variety of purposes including the discovery of diagnostics and therapeutics for this disease.
- mammals in which two or more genes have been knocked out or knocked in, or both.
- Such mammals can be generated by repeating the procedures set forth herein for generating each knockout construct, or by breeding to mammals, each with a single gene knocked out, to each other, and screening for those with the double knockout genotype.
- Regulated knockout animals can be prepared using various systems, such as the tet-repressor system (see U.S. Pat. No. 5,654,168) or the Cre-Lox system (see U.S. Pat. No. 4,959,317 and No. 5,801,030).
- Transgenic mammals can be prepared for evaluating the molecular mechanisms of PAMP, and particularly human PAMP function. Such mammals provide excellent models for screening or testing drug candidates. It is possible to evaluate compounds or diseases on “knockout” animals, e.g., to identify a compound that can compensate for a defect in PAMP activity.
- PAMP or mutant PAMP
- ⁇ APP ⁇ APP
- PS1, PS2, and/or Notch or some other component (double or triple transgenics) “knock-in” mammals can be prepared for evaluating the molecular biology of this system in greater detail than is possible with human subjects. Both technologies permit manipulation of single units of genetic information in their natural position in a cell genome and to examine the results of that manipulation in the background of a terminally differentiated organism.
- These animals can be evaluated for levels of mRNA or protein expression, processing of ⁇ APP, or development of a condition indicative of inappropriate gene expression, e.g., Notch phenotype or another phenotype as set forth above, or neurodegeneration, including cognitive deficits, learning or memory deficits, or neuromuscular deficits.
- a condition indicative of inappropriate gene expression e.g., Notch phenotype or another phenotype as set forth above, or neurodegeneration, including cognitive deficits, learning or memory deficits, or neuromuscular deficits.
- transgenic animal systems have been developed. Mice, rats, hamsters, and other rodents are popular, particularly for drug testing, because large numbers of transgenic animals can be bred economically and rapidly. Larger animals, including sheep, goats, pigs, and cows, have been made transgenic as well. Transgenic D. melanogaster and C. elegans can also be made and, using known genetic methods, may offer the ability to identify upstream and downstream modifiers of a PAMP phenotype. Transgenic animals can also be prepared by introducing the transgene on a vector; such animals, which are not modified in the germ line and are only transiently transgenic, naturally cannot pass along the genetic information to their progeny.
- transgenic animals are created in which (i) a human PAMP, or a mutant human PAMP, is stably inserted into the genome of the transgenic animal; and/or (ii) the endogenous PAMP genes are inactivated and replaced with their human counterparts. See, e.g., Coffman, 1997; Esther et al., 1996; Murakami et al, 1996. Such animals can be treated with candidate compounds and monitored for the effects of such drugs on PAMP cavity.
- the present invention provides for treatment of such deficits either with a drug discovered using a screening assay or transgenic animal model, or both, as set forth above, or by replacing a defective PAMP gene with a functional gene by gene therapy.
- a gene encoding PAMP, a PAMP mutant, or alternatively a negative regulator of PAMP such as an antisense nucleic acid, intracellular antibody (intrabody), or dominant negative PAMP (which may be truncated), can be introduced in vivo, ex vivo, or in vitro using a viral or a non-viral vector, e.g., as discussed above.
- Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both. Targeted gene delivery is described in WO 95/28494, published October 1995.
- an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, e.g., adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells.
- the viral vector e.g., adenovirus vector
- immunosuppressive cytokines such as interleukin 12 (IL 12), interferon- ⁇ (IFN ⁇ ), or anti-CD4 antibody
- IL 12 interleukin 12
- IFN ⁇ interferon- ⁇
- anti-CD4 antibody can be administered to block humoral or cellular immune responses to the viral vectors (see, e.g., Wilson, 1995).
- IL 12 interleukin 12
- IFN ⁇ interferon- ⁇
- anti-CD4 antibody can be administered to block humoral or cellular immune responses to the viral vectors (see, e.g., Wilson, 1995).
- herpes virus vectors Because herpes virus is trophic for cells of the nervous system (neural cells), it is an attractive vector for delivery of function PAMP genes.
- Various defective (non-replicating, and thus non-infectious) herpes virus vectors have been described, such as a defective herpes virus 1 (HSV 1) vector (Kaplitt et al., 1991; International Patent Publication No. WO 94/21807, published Sep. 29, 1994; International Patent Publication No. WO 92/05263, published Apr. 2, 1994).
- HSV 1 herpes virus 1
- Adenovirus vectors are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types in vivo, and has been used extensively in gene therapy protocols, including for targeting genes to neural cells.
- Various serotypes of adenovirus exist. Of these serotypes, preference is given to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914).
- adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard et al., 1990), ovine, porcine, avian, and simian (example: SAV) origin.
- the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g., Manhattan or A26/61 strain (ATCC VR-800), for example).
- replication defective adenovirus and minimum adenovirus vectors have been described for gene therapy (WO94/26914, WO95/02697, WO94/28938, WO94/28152, WO94/12649, WO95/02697 WO96/22378).
- the replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al., 1991; EP 185 573; Graham, 1984; Graham et al., 1977). Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.
- Adeno-associated viruses are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies.
- the AAV genome has been cloned, sequenced and characterized.
- the use of vectors derived from the AAVs for transferring genes in vitro and in vivo has been described (see WO 91/18088; WO 93/09239; U.S. Pat. No. 4,797,368, U.S. Pat. No. 5,139,941, EP 488528).
- the replication defective recombinant AAVs according to the invention can be prepared by co-transfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus).
- ITR inverted terminal repeat
- Retrovirus vectors In another embodiment the gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Pat. No. 5,399,346; Mann et al., 1983; Temin et al., U.S. Pat. No. 4,650,764; Temin et al., U.S. Pat. No. 4,980,289; Markowitz et al. 1988; Temin et al., U.S. Pat. No. 5,124,263; EP 453242, EP178220; Bernstein et al., 1985; McCormick, 1985; International Patent Publication No. WO 95/07358, published Mar.
- the retroviruses are integrating viruses which infect dividing cells.
- the retrovirus genome includes two LTRs, an encapsidation sequence and three coding regions (gag, pol and env).
- the gag, pol and env genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest.
- These vectors can be constructed from different types of retrovirus, such as MoMuLV (“murine Moloney leukemia virus”), MEV (“murine Moloney sarcoma virus”), HASV (“Harvey sarcoma virus”); SNV (“spleen necrosis virus”), RSV (“Rous sarcoma virus”) and Friend virus.
- Suitable packaging cell lines have been described in the prior art, in particular the cell line PA317 (U.S. Pat. No. 4,861,719); the PsiCRIP cell line (WO 90/02806) and the GP+envAm-12 cell line (WO 89/07150).
- the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsidation sequences which may include a part of the gag gene (Bender et al., 1987). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.
- Retrovirus vectors can also be introduced by recombinant DNA viruses, which permits one cycle of retroviral replication and amplifies transfection efficiency (see WO 95/22617, WO 95/26411, WO 96/39036, WO 97/19182).
- Lentivirus vectors are can be used as agents for the direct delivery and sustained expression of a transgene in several tissue types, including brain, retina, muscle, liver and blood.
- the vectors can efficiently transduce dividing and non-dividing cells in these tissues, and maintain long-term expression of the gene of interest.
- Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of high-titer lentivirus vectors for gene therapy.
- An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line which can generate virus particles at titers greater than 106 IU/ml for at least 3 to 4 days (Kafri, et al., 1999).
- the vector produced by the inducible cell line can be concentrated as needed for efficiently transducing nondividing cells in vitro and in vivo.
- Non-viral vectors A vector can be introduced in vivo in a non-viral vector, e.g., by lipofection, with other transfection facilitating agents (peptides, polymers, etc.), or as naked DNA.
- Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection, with targeting in some instances (Felgner, et. al., 1987; Felgner and Ringold, 1989; see Mackey, et al., 1988; Ulmer et al., 1993).
- Useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and WO96/17823, and in U.S. Pat. No. 5,459,127.
- a nucleic acid in vivo such as a cationic oligopeptide (e.g., International Patent Publication WO95/21931), peptides derived from DNA binding proteins (e.g., International Patent Publication WO96/25508), or a cationic polymer (e.g., International Patent Publication WO95/21931).
- electrotransfer a relatively low voltage, high efficiency in vivo DNA transfer technique, termed electrotransfer, has been described (Mir et al., 1998; WO 99/01157; WO 99/01158; WO 99/01175).
- DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun (ballistic transfection), or use of a DNA vector transporter (see, e.g., Wu et al., 1992; Wu and Wu, 1988; Hartmut et al., Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990; Williams et al., 1991). Receptor-mediated DNA delivery approaches can also be used (Curiel et al., 1992; Wu and Wu, 1987).
- U.S. Pat. Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal.
- Antibodies against PS1, PS2 and ⁇ APP An antibody, termed 1142, directed against PS1, was raised to a peptide segment corresponding to residues 30-45 of PS1 (Levesque et al., 1998; Yu et al., 1998).
- the peptide was synthesized by solid-phase techniques and purified by reverse phase high pressure liquid chromatography (HPLC).
- Peptide antigens were linked to keyhole limpet hemocyanin (KLH) and used, in combination with complete Freud's adjuvant, to innoculate New Zealand White rabbits.
- KLH keyhole limpet hemocyanin
- Antisera from three rabbits was pooled, ammonium precipitated and the antibody was purified with Sulfo-link (Pierce) agarose-peptide affinity columns.
- antibodies used include antibody 369, a polyclonal rabbit-anti-human antibody directed against the C-terminus of human ⁇ APP (Buxbaum et al., 1990); antibody 14 (Ab 14), a rabbit polyclonal antibody raised against residues 1-25 of human PS1 (Seeger et al., 1997); antibody ⁇ -PS1-CTF, a polyclonal rabbit antibody directed against the PS1 loop; and antibody DT2, a monoclonal antibody raised to a GST-fusion protein containing the PS2 N-terminal sequence from residues 1-87.
- HEK Human embryonic kidney cells
- AEBSF 4-(2-aminoethyl)-benzenesulfonyl fluoride
- the cell homogenates were centrifuged 1000 ⁇ g for 10 minutes to remove cell debris. The supernatant was then centrifuged 10,000 ⁇ g for 60 minutes. The resulting membrane pellet was resuspended in Buffer B (20 mM HEPES pH 7.2, 1 M KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitor cocktail as above) and incubated for 45 minutes with agitation at 4° C. Cell membranes were collected again by centrifugation at 107,000 ⁇ g for 60 minutes.
- Buffer B (20 mM HEPES pH 7.2, 1 M KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitor cocktail as above
- the cell membranes were then lysed on ice for 60 minutes with Buffer C (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitors cocktail). After spinning 10,000 ⁇ g for 15 minutes, the protein extract was adjusted with Buffer C to contain 5 mg/ml protein. A total of 0.5 g of protein was obtained.
- Buffer C 1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitors cocktail. After spinning 10,000 ⁇ g for 15 minutes, the protein extract was adjusted with Buffer C to contain 5 mg/ml protein. A total of 0.5 g of protein was obtained.
- the Protein A/G agarose beads were washed three times with Buffer D (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, protease inhibitors cocktail), and three times with Buffer E (0.5% Digitonin, 0.5% CHAPS, 20 mM HEPES pH 7.2, 100 mM KCl, 10 mM CaCl 2 , 5 mM MgCl 2 , and the protease inhibitor cocktail as above). Isolated protein complexes were eluted from the beads with 0.1M Glycine-HCl, pH 3.0, and then neutralized with 1M Tris.
- Buffer D 1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, protease inhibitors cocktail
- Buffer E 0.5% Digitonin, 0.5% CHAPS, 20 mM HEPES pH 7.2, 100 mM KCl, 10 mM CaCl 2 , 5 mM Mg
- Proteins were then separated by Tris-Glycine SDS-PAGE gels and stained with silver stain and Coomassie Blue stain. The staining of the immuno-purified proteins displayed two intense bands in addition to those of the presenilin holoprotein and its fragments.
- Sequence analysis Individual protein bands were cut out and analyzed with solid-phase extraction capillary electrophoresis mass spectrometry/mass spectrometry (SPE-CE-MS/MS). Briefly, protein bands were first digested in gel with trypsin; the digested proteins were extracted and dried in a speed vacuum down to concentrate the peptides; and the peptides thereafter separated with micro LC and analyzed by on-line tandem mass spectrometry (Figeys et al., 1999). Nucleotide and amino acid sequence homology searches were conducted using the BLAST algorithm, and motif analyses performed using the program BLOCKS.
- PAMP cDNAs were obtained using oligonucleotides designed from partial cDNA/EST sequences in public databases to screen appropriate cDNA libraries, for 5′RACE, and/or for RT-PCR experiments.
- a PAMP expression construct was generated by inserting human PAMP cDNA in-frame with the V5 epitope of pcDNA6 (Invitrogen) at the C-terminus of PAMP.
- HEK293 cells with a stable expression of PS1/PS2 and ⁇ APP sw were transiently transfected with either V5-tagged PAMP or empty plasmid (mock transfection control).
- V5-PAMP and ⁇ APP 695 were transient transfections of V5-PAMP and ⁇ APP 695 (or empty vector plus ⁇ APP 695 as a mock transfection control) into murine embryonic fibroblasts stably infected with human PS1 expressed from a retroviral vector construct (Clontech, CA); or (2) transient transfection of V5-PAMP (or an empty plasmid) into HEK293 cell lines with a stable expression of the C-terminal 99 amino acids of ⁇ APP with a preceding artificial signal peptide (spC100-APP) together with either wild type PS1, PS1-L392V, or PS1-D385A.
- spC100-APP preceding artificial signal peptide
- PS1 was immunodetected or immunoprecipitated with antibodies 14 or a-PS1-CTF; and PS2 was immunodetected or immunoprecipitated with antibody DT2.
- FL- ⁇ APP and its C-terminal ⁇ - and ⁇ -secretase derivatives were detected using antibody 369.
- the cDNA sequence predicted an open reading frame of 709 amino acids (SEQ ID NO: 14), which contains a putative N-terminal signal peptide, a long N-terminal hydrophilic domain with sequence motifs for glycosylation, N-myristoylation and phosphorylation, a ⁇ 20 residue hydrophobic putative transmembrane domain, and a short hydrophilic C-terminus of 20 residues ( FIGS. 1A and 1B ).
- HEK293 cells were transiently transfected with PAMP cDNA (SEQ ID NO: 13) tagged at the 3′-end with a V5-epitope encoded from the pcDNA6 vector.
- the conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the A ⁇ 40 and A ⁇ 42 levels were measured by ELISA (Zhang L, et al., 1999).
- the PAMP gene Chromosomal locations and genetic map positions of the murine and human PAMPS were obtained from public genetic and transcriptional maps (www.ncbi.nlm.nih.gov).
- the gene encoding PAMP is located on human chromosome 1 near the genetic markers D151595 and D1S2844.
- the 5′-end of the PAMP gene is embedded in the 5′-end of the coatmer gene encoded on the opposite strand.
- the human PAMP gene is close to a cluster of markers which have yielded positive, but sub-significant evidence for linkage to or association with Alzheimer Disease in two independent genome wide surveys (Kehoe et al., 1999).
- the murine PAMP maps within a 700 Kb interval of murine chromosome 1 which contains the gene defect associated with Looptail phenotype in mice (Underhill et al., 1999). Mice heterozygous for Looptail show developmental defects in dorsal axial structures including notochord, brain, spinal cord, and somites (Greene et al., 1998), which are reminiscent of those observed in PS1 ⁇ / ⁇ mice (Shen J, et al., 1997; Wong et al., 1997). These observations suggest that the presenilin: PAMP complex may be involved in both ⁇ APP and Notch processing.
- the C. elegans homolog of PAMP corresponds to the aph-2 gene. Mutations in aph-2 have been identified in a screen for mutants with phenotypes identical to embryonic mutant phenotypes caused by loss of glp-1 activity, i.e., lack of an anterior pharynx, e.g. cDNA clone.
- the EST corresponding to aph-2, (cDNA clone yk477b8, kindly provided by Y. Kohara, National Institute of Genetics, Japan) was sequenced and the coding region (SEQ ID NO: 11) found to match exactly the Genefinder prediction made by the C.
- RNAi Double stranded RNA interference
- Sense and antisense RNA were transcribed in vitro from PCR product amplified from the phage yk477b8. After annealing equal quantities of sense and antisense products, the dsRNA product made was injected into L4 stage wild-type worms. The chosen line of worms, designated lin-12(n302) (Greenwald and Seydoux, 1990; Greenwald, et al., 1983) was obtained from the Caenorhabditis Genetics Center.
- Injected animals were transferred to fresh plates daily and the progeny scored at least 36 hours after injection for the embryonic lethal phenotype and 4-5 days after injection for the egg-laying phenotypes.
- Animals injected with dsRNA from yk477b8 template produced eggs that lacked an anterior pharynx.
- the PS1-D385A mutation is a loss of function mutation associated with inhibition of PS1 endoproteolysis and a decrease in ⁇ -secretase activity (Wolfe et al., 1999).
- the conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the A ⁇ 40 and A ⁇ 42 levels were measured by ELISA (Zhang et al., 1999).
- Analysis of Western blots from these co-immunoprecipitation experiments revealed that PAMP holoprotein (and C-terminally tagged proteolytic fragments of PAMP) interacted in equivalent degrees with wild type PS1, wild type PS2, PS1-L392V mutant, and PS1-D385A mutant proteins.
- PAMP holoprotein and the C-terminal proteolytic fragments of PAMP also co-immunoprecipitated with the C-terminal proteolytic fragments of ⁇ APP but not ⁇ APP holoprotein in lysates of cells expressing either ⁇ APP holoprotein or just the C-terminal 99 amino acids of ⁇ APP.
- cell lines expressing pathogenic mutations of PS1 showed increased amounts of C-terminal ⁇ APP fragments co-immunoprecipitating with PAMP.
- Presenilin binding domains of PAMP In transiently transfected cells (in which the 7-10 kDa C-terminal of PAMP can be detected), anti-PS1 immunoprecipitation products contain both full length PAMP and the 7-10 kDa C-terminal PAMP fragments. Similarly, in these cells, immunoprecipitation with antibodies to the C-terminus of ⁇ APP (Ab369) also renders C-terminal nicastrin epitopes.
- the TM domain of PAMP is not highly conserved in evolution.
- Looptail has a number of phenotypic similarities to those of Notch and PS1 knockouts in mice. Because Looptail is a model of human spinal cord malformations including spina bifida, PAMP biology may also provide some useful insights into this neurological developmental defect as well.
- PAMP may be involved in the function of PS1 and PS2 complexes by binding substrates for ⁇ -secretase.
- PAMP may have a regulatory role on the activity of the presenilin complexes. This is consistent with the observation that residues 625-641 of human and murine PAMP contain a motif similar to cyclic nucleotide binding domains of several other unrelated proteins.
- PAMP selectively interacts only with C-terminal derivatives of ⁇ APP which are substrates for ⁇ -secretase cleavage, and this interaction is modulated by PS1 mutations in a way which reflects the functional consequences of these PS1 mutations.
- inhibition of PAMP expression in C. elegans leads to a disease phenotype likely to be in the glp/Notch signaling pathway.
- PAMP cDNAs harboring the above mutations as well as normal/wild type PAMP (PAMP wt ) cDNA and the cDNA for an unrelated protein (LacZ), in frame into pcDNA6 vectors.
- PAMP wt normal/wild type PAMP
- LacZ unrelated protein
- both A ⁇ 40 and A ⁇ 42 levels were increased, and there was also a 68% increase in A ⁇ 42 /A ⁇ 40 ratio which is very similar to that observed in clinical mutations in APP, PS1, and PS2, associated with early onset Alzheimer Disease.
- the A ⁇ 42 /A ⁇ 40 ratio was also increased in one cell line expressing the PAMP C230A mutant.
- both the total A ⁇ 42 and A ⁇ 40 levels and the A ⁇ 42 /A ⁇ 40 ratio were massively reduced (to only 18% of the control) in the PAMP ⁇ 312-369 mutant.
- a similar but less profound reduction of both the total A ⁇ 42 and A ⁇ 40 levels and the A ⁇ 42 /A ⁇ 40 ratio was observed in the conditioned medium from the PAMP ⁇ 312-340 cell lines.
- PAMP mutants cause biochemical changes similar to those induced by mutations in the ⁇ APP, PS1, and PS2 genes which give rise to AD, and which may be implicated also in schizophrenia.
- These artificial PAMP mutations can therefore be used to generate cellular and other model systems to design treatments and preventions for schizophrenia, AD and other neurodegenerative and/or neuropsychiatric disorders.
- These mutations also show that PAMP is involved in the pathogenesis of AD, and may provide information for the design of specific molecular diagnostics or therapeutics for schizophrenia, AD, and other neurological disorders.
- missense mutation of the conserved DYIGS motif to AAIGS caused a significant increase in A ⁇ 42 secretion, a smaller increase in A ⁇ 40 secretion, and an increase in the A ⁇ 42 /A ⁇ 40 ratio (p ⁇ 0.001; Table 2). This increase in A ⁇ 42 production was equivalent to that of FAD-related missense mutations in PS1.
- This domain contains no obvious functional motifs (e.g., for glycosylation etc.), nor does it have significant sequence homology to other known proteins. Consequently, the three functionally active PAMP mutations either affect a presenilin-binding domain in PAMP, or affect a specific regulatory domain of PAMP which modulates both direct binding of PAMP to PS1 and the subsequent ⁇ -secretase-mediated cleavage of PAMP-bound C99- and C83- ⁇ APP stubs.
- Notch cDNA was tagged with myc to the membrane-portion of Notch or to the soluble proteolytic derivative called Notch intra-cellular domain (NICD).
- Notch intra-cellular domain NBD
- V5-epitope-tagged PAMP and myc-tagged-Notch cDNAs were co-transfected into HEK293 cells. Thereafter, V5-tagged-PAMP was immunoprecipitated with anti-V5-antibodies, and the immunoprecipitation products investigated for myc-tagged proteins. In the immunoprecipitate, myc-tagged-Notch was found, but not myc-tagged-NICD.
- study objects are selected from families having (1) increased rates of schizophrenia, and (2) a high proportion linked to the susceptibility locus on chromosome 1 q21-q22 as described in Brzustowicz et al., 2000.
- Control individuals are selected from families with no or only a rare occurrence of schizophrenia.
- Tissue samples are collected from study objects and control objects.
- the samples can be obtained either by sampling tissue fluids such as blood and cerebrospinal fluid, or by taking biopsies from selected tissues. In certain instances it may be preferable to collect tissue biopsies, e.g. from brain, kidney, or lung, from deceased study or control objects, i.e. post-mortem.
- the samples are analyzed for at least one of the following: (1) sequence of the entire or selected portions of the PAMP gene; (2) sequence and levels of PAMP mRNA; (3) sequence, levels, and activity of PAMP protein; (4) levels of a PAMP substrate. Identification of relevant mutations in the PAMP gene or mRNA is performed by using PCR together with primers specific for PAMP DNA or mRNA and radiolabeled nucleotides, hybridization analysis, and/or other automated sequencing techniques described herein or in references provided in the present disclosure, which are all incorporated by reference.
- Mutations in and levels of the PAMP protein is studied by, e.g., purifying PAMP from the tissue sample, performing enzyme-linked immunosorbent assay (ELISA) or other quantitative or semi-quantitative immunoassays, Edman degradation analysis, mass-spectroscopy, Western blotting, or other analytical techniques described herein or in references in the present disclosure.
- ELISA enzyme-linked immunosorbent assay
- other quantitative or semi-quantitative immunoassays Edman degradation analysis, mass-spectroscopy, Western blotting, or other analytical techniques described herein or in references in the present disclosure.
- PAMP biological activity assays are conducted as described herein by either in vivo methods (e.g., monitoring ⁇ APP processing and the production of amyloid- ⁇ peptide (A ⁇ ), or other suitable protein substrates for PAMP including Notch, etc.), or by in vitro assays (using either whole cell or cell-free assays to measure processing of suitable substrates including ⁇ APP or parts thereof, and other proteins such as Notch).
- in vivo methods e.g., monitoring ⁇ APP processing and the production of amyloid- ⁇ peptide (A ⁇ ), or other suitable protein substrates for PAMP including Notch, etc.
- in vitro assays using either whole cell or cell-free assays to measure processing of suitable substrates including ⁇ APP or parts thereof, and other proteins such as Notch.
- PAMP or PAMP mutations, or altered PAMP or PAMP levels, identified in this manner can advantageously be used in the creation of in vivo assays (e.g., transgenic animals) or in vitro assays to study induction and/or progression of schizophrenia, as well as in the screening of potential therapeutic agents for schizophrenia.
- in vivo assays e.g., transgenic animals
- in vitro assays to study induction and/or progression of schizophrenia
- potential therapeutic agents for schizophrenia for instance, in an in vivo transgenic/recombinant mouse model, partial phenotypes could be examined via behavioral deficits in, e.g., exploratory behavior, novelty seeking, cognitive flexibility/rigidity, sensitivity to dopamine-induced motor disturbances, etc. (see Cloninger et al., 1996).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Abstract
Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided. PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodevelopmental and neuropsychiatric disorders. In a specific embodiment, mutations in PAMP are diagnostic for schizophrenia. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodevelopmental and neuropsychiatric disorders, particularly schizophrenia. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical, morphological, or neuropsychological changes similar to those associated with schizophrenia.
Description
- This patent application claims the priority of U.S. provisional patent application No. 60/229,889, filed Sep. 1, 2000, which is incorporated herein by reference in its entirety.
- The present invention relates generally to the field of neurological and physiological dysfunctions associated with neuropsychiatric and neurodevelopmental diseases, especially schizophrenia. More particularly, the invention is concerned with the identification of proteins associated with neuropsychiatric and neurodevelopmental diseases, especially schizophrenia, and relates to methods of diagnosing these diseases, and to methods of screening for candidate compounds which modulate the interaction of a certain protein, specifically Presenilin Associated Membrane Protein (“PAMP”), with presenilin proteins.
- The origin of and causes for schizophrenia, one of the most serious neuropsychiatric disorders, have long been sought after. A number of studies have suggested that schizophrenia is predominantly genetic, but it has proven difficult to show a significant genetic linkage. However, recently, a novel locus associated with inherited susceptibility to schizophrenia has been mapped to chromosome 1q21-q22, near the anonymous DNA markers D1S1653, D1S1679, and D1S1677 (Brzustowicz et al., 2000). Furthermore, several lines of evidence, both from morphological and neuropsychological findings, now indicate that schizophrenia may be a disease of central nervous system development (reviewed in Stefan et al, 1997). For example, Falkai et al., 2000, provided quantitative data showing that the positioning of neuron (pre-alpha cell) clusters was abnormal in schizophrenia patients, supporting the theory that schizophrenia derives from impaired brain development. Such abnormal neuron positions could, e.g., arise from failures of neuronal migration during fetal development.
- An important pathway implicated in the development of the nervous system, as well as in schizophrenia, is the Notch signaling pathway. Notch is a protein receptor for inhibitory signals that shape the pattern of the nervous system, and the localization of Notch signaling is crucial for determining where neural precursor cells arise (Baker, 2000). In a series of 80 British parent-offspring trios, the NOTCH4 locus was highly associated with schizophrenia (Wei and Hemmings, 2000). Possible candidate sites conferring susceptibility to schizophrenia included an A-to-G substitution in the promoter region, and the (CTG)n repeat in
exon 1, of NOTCH4. - The presenilin proteins, i.e., presenilin 1 (PS1, encoded by the PS1 gene) and 2 (PS2, encoded by the PS2 gene), are involved in the Notch pathway, and form a close functional relationship with Notch during cell fate determination in a variety of species (Selkoe, 2000). Several lines of evidence have suggested roles for PS1 and PS2 genes in developmental, apoptotic signaling and in the regulation of proteolytic cleavage of the β-amyloid precursor protein (βAPP) (Levitan et al., 1995; Wong et al., 1997; Shen et al., 1997; Wolozin et al., 1996; De Strooper et al., 1998). For example, the PS1 gene is associated with migration defects in the central nervous system of PS1−/− mice (Hartmann et al., 1999; Handler et al., 2000). In addition, a mutation in βAPP (βAPPAla713Val) has been described in one family with a schizophrenia-like illness (Jones et al., 1992), further implicating the PS1/βAPP/Notch pathways in schizophrenia and related disorders. However, just how these putative functions are mediated, and how they relate to the abnormal metabolism of the βAPP associated with PS1 and PS2 mutations remains to be elucidated (Martin et al., 1995; Scheuner et al., 1996; Citron et al., 1997; Duff et al., 1996; Borchelt et al., 1996). The identification and cloning of normal as well as
mutant PS 1 and PS2 genes and gene products are described in detail in co-pending commonly assigned U.S. application Ser. No. 08/431,048, filed Apr. 28, 1995; Ser. No. 08/496,841, filed Jun. 28, 1995; Ser. No. 08/509,359, filed Jul. 31, 1995; and Ser. No. 08/592,541, filed Jan. 26, 1996, the disclosures of which are incorporated herein by reference. - A new protein which specifically interacts with PS1 and PS2 has recently been discovered. This transmembrane protein, herein referred to as “Presenilin Associated Membrane Protein” or “PAMP”, is expressed in multiple tissues (e.g., brain, kidney, lung, etc.). PAMP is described in co-pending commonly assigned U.S. application Ser. No. 09/541,094, filed Mar. 31, 2000, which is specifically incorporated herein by reference. The PAMP gene and gene product is implicated in the biochemical pathways affected in Alzheimer's Disease (AD), and may also have a role in other dementias, amyloid angiopathies, and developmental disorders such as spina bifida. Interestingly, the gene associated with inherited susceptibility to schizophrenia (see Brzustowicz, supra) also contains the PAMP gene (Yu et al, 2000).
- A need exists for new methods and reagents to more accurately and effectively diagnose and treat schizophrenia as well as other neuropsychiatric, neurodevelopmental, and neurodegenerative diseases. In addition, further insights into PAMP and its interaction with PS proteins and other components may lead to new diagnostic and treatment methods for schizophrenia and other related CNS diseases.
- The present invention provides new uses of the PAMP gene, the product of the gene, and mutations and polymorphisms thereof in the study and treatment of a variety of neurological disorders, especially schizophrenia. Applicants have surprisingly discovered that PAMP plays a role in the development of schizophrenia. The PAMP gene and the product of the PAMP gene therefore present new therapeutic targets for the treatment of a variety of neurological disorders, especially schizophrenia. Moreover, the PAMP gene will be useful for generating animal and cellular models of schizophrenia.
- Thus, PAMP nucleic acids, proteins and peptides, antibodies to PAMP, cells transformed with PAMP nucleic acids, and transgenic animals altered with PAMP nucleic acids that possess various utilities, are described herein for the diagnosis, therapy and continued investigation of neuropsychiatric and neurodevelopmental disorders, especially schizophrenia. Furthermore, mutant PAMP nucleic acids, proteins, or peptides, cells transfected with vectors comprising mutant PAMP nucleic acids, transgenic animals expressing mutant PAMP or peptides thereof, and their use in studying neuropsychiatric and neurodevelopmental disorders, especially schizophrenia, or developing improved diagnostic or therapeutic methods for such disorders, are presented herein.
- The invention provides a method for detecting a mutation in PAMP associated with neuropsychiatric and neurodevelopmental disorders, especially schizophrenia, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having schizophrenia or another neuropsychiatric or neurodevelopmental disorder, and sequencing a gene encoding PAMP from said sample. In particular, such methods can identify normal human alleles as well as mutant alleles of PAMP genes which are causative of or contribute to neuropsychiatric or neurodevelopmental diseases, especially schizophrenia.
- The invention also provides a method for diagnosing individuals predisposed to or having a neuropsychiatric and/or neurodevelopmental disorder such as schizophrenia, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having such a disorder, and sequencing a gene encoding PAMP from said sample.
- The invention also provides a method for diagnosing individuals predisposed to or having a neuropsychiatric and/or neurodevelopmental disorder such as schizophrenia, comprising obtaining cells that contain nucleic acid encoding PAMP, and under non-pathological conditions, transcribing the nucleic acid, and measuring a level of transcriptional activity of the nucleic acid.
- The invention further provides a method for diagnosing individuals predisposed to or having a neuropsychiatric or neurodevelopmental disorder, especially schizophrenia, comprising obtaining cells from an individual that express nucleic acid encoding PAMP, and measuring PAMP activity. Alternatively, PAMP could be isolated from that individual to investigate, for example, whether the PAMP amino acid sequence is similar or different from wild-type PAMP, and/or whether PAMP expression levels differ from typical PAMP levels. In an alternative embodiment, the activity or abundance of a PAMP substrate may be measured.
- The invention also provides a method for identifying putative agents that affect a neuropsychiatric and/or neurodevelopmental disorder, especially schizophrenia, comprising administering one or more putative agents to a transgenic animal and detecting a change in PAMP activity.
- The invention also provides a method for identifying putative agents that affect a neuropsychiatric and/or neurodevelopmental disorder, especially schizophrenia, comprising adding one or more said agents to the reconstituted system described above, and detecting a change in PAMP activity.
- The invention also provides a method for identifying putative agents that affect a neuropsychiatric and/or neurodevelopmental disorder, especially schizophrenia, comprising adding one or more said agents to the complex described above, and detecting a conformational change in PAMP.
- The invention also provides a method for identifying proteins that interact with PAMP, comprising contacting a substance to the reconstituted system discussed above, and detecting a change in PAMP activity.
- The invention also provides animal and cellular models of schizophrenia or related disorders that comprise a PAMP gene as a therapeutic target for the development of drugs which interact with PAMP, and thus may be useful in the treatment and prevention of schizophrenia or related disorders.
- Further the invention provides for a method for identifying substances that modulate PAMP activity, comprising contacting a sample containing one or more substances with PAMP, or a PAMP mutant, or functional fragments thereof, and a PAMP substrate, measuring PAMP activity, and determining whether a change in PAMP activity occurs. In a preferred embodiment, the substance is a PAMP inhibitor. In another preferred embodiment, the substance stimulates PAMP activity.
- These and other aspects of the invention are further elaborated in the Detailed Description of the Invention and Examples, infra.
-
FIGS. 1A and 1B . Predicted amino acid sequences for human (SEQ ID NO: 14), mouse (SEQ ID NO: 16), D. melanogaster (SEQ ID NO:18) and C. elegans (SEQ ID NO: 12) PAMP orthologues. - According to the invention, the PAMP gene and its product, the PAMP protein, present new therapeutic targets for the treatment of a variety of neurological disorders, especially schizophrenia. Provided herein are also new strategies to create animal and cellular models based on PAMP or PAMP mutants to study schizophrenia and potential treatment strategies. The invention also offers the potential for new diagnostic screening methods for schizophrenia, wherein the PAMP gene and PAMP protein are investigated.
- The invention is based, in part, on the discovery that the PAMP gene and the PAMP protein play critical roles in schizophrenia and other neuropsychiatric disorders. PAMP (“Presenilin Associated Membrane Protein”), is a novel Type I transmembrane protein that is closely involved in CNS development via its interactions with Notch processing, PS1, PS2 and with the α- and β-secretase derived fragments of βAPP. Multiple studies have indicated that defects in CNS development, such as defects in neuronal migration, are associated with schizophrenia, and PAMP is linked to this disorder through several lines of evidence, such as (1) the PAMP gene maps to the same location as the schizophrenia susceptibility gene, as described above; (2) PAMP interacts with PS1, which is associated with migration defects in the central nervous system in PS I−/− mice (see above); (3) PAMP is involved in the Notch signaling pathway, one gene locus of which (NOTCH4) is implicated in schizophrenia (see above); and (4) a mutation in βAPP is associated with a schizophrenia-like illness (see above). Therefore, PAMP can contribute to the development of schizophrenia via several routes, e.g., through mutations and/or polymorphisms in PAMP, variations in its expression levels, and defects in its interactions with other components in neural development and/or migration.
- As referred to herein, “PAMP” means a native or mutant full-length protein, or fragments thereof, that interacts with the PAMP-interacting domain of a presenilin protein. PAMP is also known under the name “Nicastrin”. Human, murine, D. melanogaster and C. elegans orthologues are provided.
- Experimental data indicate that PAMP, PS1, and PS2 exist in the same high molecular weight protein complex, and PAMP and PS1 are both co-localized to intracellular membranes in the endoplasmic reticulum and Golgi apparatus. Abolition of functional expression of a C. elegans homologue of this protein leads to the development of notch-like developmental defects. This shows that PAMP is also intimately involved in the processing of not only βAPP, but also other molecules, such as Notch and its homologues. For example, PAMP can bind to membrane-bound Notch. From expressed sequence tags (EST) databases, it is apparent that, like PS1 and PS2, PAMP is expressed in multiple tissues.
- Various structural features characterize PAMP (GenBank Accession No. Q92542; SEQ ID NO: 14). The nucleotide sequence (SEQ ID NO: 13) of human PAMP predicts that the gene encodes a
Type 1 transmembrane protein of 709 amino acids (SEQ ID NO: 14), the protein having a short hydrophilic C-terminus (˜20 residues), a hydrophobic transmembrane domain (15-20 residues), and a longer N-terminal hydrophilic domain which contains several potentially functional sequence motifs as listed below in Table 1. The PAMP sequence also contains a Trp-Asp (WD) repeat (residue 226), at least one “DTG” motif (residues 91-93) present in eukaryotic aspartyl proteases, as well as several “TDTA/DTAE” motifs (residues 480-482, 504-506) present in viral aspartyl proteases. There are also four conserved cysteine residues in the N-terminal hydrophilic domain (Cys195, Cys213, Cys230, and Cys248 in human PAMP) having a periodocity of 16-17 residues, which may form a functional domain (e.g. a metal binding domain or disulfide bridge for tertiary structure stabilization). Subdomains of PAMP have weak homologies to a variety of peptidases. For example, residues 322-343, 361-405, and 451-466 have 46% (p=0.03) similarity to another hypothetical protein; C. elegans aminopeptidase hydrolase precursor signal antigen transmembrane receptor zinc glycoprotein (SWISS-PROT; see expasy.ch/sprot on the World-Wide Web (www); Accession No. Q93332).TABLE 1 Potential functional sequence motifs in PAMP (SEQ ID NO: 14). Potential function PAMP residue (amino acid sequence) N-asparaginyl glycosylation 45 (NKTA), 55 (NATH), 187 (NETK), 200 (NLSQ), 204 (NGSA), 264 (NTTG), 387 (NESV), 417 (NQSQ), 435 (NISG), 464 (NVSY), 506 (NFSD), 530 (NNSW), 562 (NTTY), 573 (NLTG), 580 (NLTR), 612 (NETD) Glycosaminoglycan attachment 404 (SGAG) Myristolation 5 (GGGSGA), 29 (GLCRGN), 61 (GCQSSI), 120 (GLAVSL), 146 (GVYSNS), 167 (GNGLAY), 205 (GSAPTF), 294 (GAESAV), 438 (GVVLAD), 446 (GAFHNK), 504 (GTNFSD), 576 (GTVVNL) Phosphorylation sites for cAMP- and 232 (RRSS) cGMP-dependent protein kinase Phosphorylation sites for protein 115 (TSR), 268 (TLK), 340 (SSR), 384 (SQK), kinase C 389 (SVR), 483 (TAK), 614 (TDR), 624 (TAR) Phosphorylation sites for casein 8 (SGAD), 280 (TRLD), 361 (SFVE), 372 (TSLE), kinase II 455 (SIYD), 466 (SYPE), 472 (SPEE), 641 (SSTE), 647 (TWTE) - The invention is further based on the identification of conserved functional domains, based on comparison and evaluation of the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), D. melanogaster (SEQ ID NO: 18), and C. elegans (SEQ ID NO: 12) orthologues of PAMP. “PAMP” can be characterized by the presence of conserved structural features, relative to orthologues from D. melanogaster and C. elegans. Nucleotide sequences encoding homologous hypothetical proteins exist in mice multiple EST, and C. elegans (GenBank; see ncbi.nlm.nih.gov on the World-Wide Web (www); Accession No. Z75 714; 37% similarity, p=8.7e−26) (Wilson et al., 1994). These hypothetical murine and nematode proteins have a similar topology and contain similar functional motifs to human PAMP. The existence of such homology predicts that similar proteins will be detected in other species including Xenopus, and Zebra fish, to mention a few such possibilities. By comparing the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), D. melanogaster (SEQ ID NO: 18), and C. elegans (SEQ ID NO: 12) PAMP proteins, we have deduced a series of conserved functional domains. One domain has chemical similarities to cyclic nucleotide binding domains of other proteins, and may have some regulatory role on a potential complex formed between PS1:PAMP and the C-terminal fragment of βAPP, derived either from α- or β-secretase. These putative functional domains are sites for therapeutic target development by deploying drugs which might interact with these sites to modulate βAPP processing via this complex.
- The term “PAMP” also refers to functionally active fragments of the protein. Such fragments include, but are not limited to, peptides that contain an epitope, e.g., as determined by conventional algorithms such as hydrophilicity/hydrophobicity analysis for antibody epitopes, and amphipathicity or consensus algorithms for T cell epitopes (Spouge et al., 1987; Margalit et al., 1987; Rothbard, 1986; Rothbard and Taylor, 1988). More preferably, a functionally active fragment of PAMP is a conserved domain, relative to the D. melanogaster and C. elegans orthologues. A specific functionally active fragment of PAMP is a fragment that interacts with PS1 or PS2, or both.
- PAMP also encompasses naturally occurring variants, including other mammalian PAMPs (readily identified, as shown herein for murine PAMP, based on the presence of the structural features set forth above), allelic variants of PAMP from other human sources (including variants containing polymorphisms that are predictive of disease propensity or of response to pharmacological agents), and mutant forms of PAMP or PAMP genes that are associated with neurological diseases and disorders (such as spina bifida), particularly neuropsychiatric disorders (such as schizophrenia). Also included are artificial PAMP mutants created by standard techniques such as site directed mutagenesis or chemical synthesis.
- A PAMP “substrate” may be a polypeptide or protein, or any other type of compound, with which PAMP interacts physiologically. Examples of PAMP substrates include PS1, PS2, and βAPP. Furthermore, A PAMP “ligand” may be a polypeptide, protein, lipid, carbohydrate, vitamin, mineral, amino acid, or any other type of compound which binds to PAMP Hypothetically, PAMP may function as a receptor which modulates PS1/PS2/βAPP processing in response to signal (ligand) dependent interactions with PAMP.
- In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, 1989; Glover, 1985; M. J. Gait, 1984; Hames &Higgins, 1985; Hames & S. J. Higgins, 1984; Freshney, 1986; IRLPress, 1986; Perbal, 1984; Ausubel et al., 1994.
- If appearing herein, the following terms shall have the definitions set out below.
- “Neuropsychiatric disorders” or “diseases” include recognized variants of overt schizophrenia (e.g., paranoid, catatonic), other related psychoses such as schizoaffective, schizotypal, schizophreniform and delusional disorders, and personality disorders such as schizoid personality disorder, schizotypal personality disorder, and paranoid personality disorder (see definitions in DSM-III-R, Diagnostic and Statistical Manual of the American Psychiatric Association; and Flaum et al., 1997).
- The use of italics (e.g., PAMP) indicates a nucleic acid molecule (cDNA, mRNA, gene, etc.); normal text (e.g., PAMP) indicates the polypeptide or protein.
- In a specific embodiment, the term “about” or “approximately” means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. Alternatively, particularly in biological systems which are often responsive to order of magnitude changes, the term about means within an order of magnitude of a given value, preferably within a multiple of about 5-fold, and more preferably within a factor of about 2-fold of a given value.
- As used herein, the term “isolated” means that the referenced material is free of components found in the natural environment in which the material is normally found. In particular, isolated biological material is free of cellular components. In the case of nucleic acid molecules, an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment. In another embodiment, an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome. In yet another embodiment, the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules can be inserted into plasmids, cosmids, artificial chromosomes, and the like. Thus, in a specific embodiment, a recombinant nucleic acid is an isolated nucleic acid. An isolated protein may be associated with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane associated protein. An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism. An isolated material may be, but need not be, purified.
- The term “purified” as used herein refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, i.e., contaminants. For example, a purified protein is preferably substantially free of other proteins or nucleic acids with which it is associated in a cell; a purified nucleic acid molecule is preferably substantially free of proteins or other unrelated nucleic acid molecules with which it can be found within a cell.
- As used herein, the term “substantially free” is used operationally, in the context of analytical testing of the material. Preferably, purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
- The term “host cell” means any cell of any organism that is selected, modified, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression by the cell of a gene, a DNA or RNA sequence, a protein or an enzyme. Host cells can further be used for screening or functional assays, as described infra. A host cell has been “transfected” by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been “transformed” by exogenous or heterologous DNA when the transfected DNA is expressed and effects a function or phenotype on the cell in which it is expressed. The term “expression system” means a host cell transformed by a compatible expression vector and cultured under suitable conditions e.g. for the expression of a protein coded for by foreign DNA carried by the vector and introduced to the host cell.
- Proteins and polypeptides can be made in the host cell by expression of recombinant DNA. As used herein, the term “polypeptide” refers to an amino acid-based polymer, which can be encoded by a nucleic acid or prepared synthetically. Polypeptides can be proteins, protein fragments, chimeric proteins, etc. Generally, the term “protein” refers to a polypeptide expressed endogenously in a cell, e.g., the naturally occurring form (or forms) of the amino acid-based polymer.
- A “coding sequence” or a sequence “encoding” an expression product, such as a RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in the production of that RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme. A coding sequence for a protein may include a start codon (usually ATG) and a stop codon.
- The coding sequences herein may be flanked by natural regulatory (expression control) sequences, or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5′- and 3′-non-coding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications.
- The term “gene”, also called a “structural gene” means a DNA sequence that codes for or corresponds to a particular sequence of ribonucleic acids or amino acids which comprise all or part of one or more proteins, and may or may not include regulatory DNA sequences, such as promoter sequences, which determine for example the conditions under which the gene is expressed.
- A “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3′ direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
- A coding sequence is “under the control” or “operatively associated with” transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which then may be trans-RNA spliced (if it contains introns) and translated into the protein encoded by the coding sequence.
- The terms “express” and “expression” mean allowing or causing the information in a gene or DNA sequence to become manifest, for example producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence. A DNA sequence is expressed in or by a cell to form an “expression product” such as a protein. The expression product itself, e.g. the resulting protein, may also be said to be “expressed” by the cell.
- The term “transfection” means the introduction of a foreign nucleic acid into a cell. The term “transformation” means the introduction of a “foreign” (i.e. extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence. The introduced gene or sequence may also be called a “cloned”, “foreign”, or “heterologous” gene or sequence, and may include regulatory or control sequences used by a cell's genetic machinery. The gene or sequence may include nonfunctional sequences or sequences with no known function. A host cell that receives and expresses introduced DNA or RNA has been “transformed” and is a “transformant” or a “clone.” The DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different genus or species.
- The terms “vector”, “cloning vector” and “expression vector” mean the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, etc. A “cassette” refers to a DNA coding sequence or segment of DNA that codes for an expression product that can be inserted into a vector at defined restriction sites. The cassette restriction sites are designed to ensure insertion of the cassette in the proper reading frame. Generally, foreign DNA is inserted at one or more restriction sites of the vector DNA, and then is carried by the vector into a host cell along with the transmissible vector DNA. A segment or sequence of DNA having inserted or added DNA, such as an expression vector, can also be called a “DNA construct.” Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes.
- A “knockout mammal” is a mammal (e.g., mouse) that contains within its genome a specific gene that has been inactivated by the method of gene targeting (see, e.g., U.S. Pat. No. 5,777,195 and No. 5,616,491). A knockout mammal includes both a heterozygote knockout (i.e., one defective allele and one wild-type allele) and a homozygous mutant. Preparation of a knockout mammal requires first introducing a nucleic acid construct that will be used to suppress expression of a particular gene into an undifferentiated cell type termed an embryonic stem cell. This cell is then injected into a mammalian embryo. A mammalian embryo with an integrated cell is then implanted into a foster mother for the duration of gestation. Zhou, et al., 1995 describes PPCA knock-out mice. Knockout mice can be used to study defects in neurological development or neurodegenerative diseases. Disease phenotypes that develop can provide a platform for further drug discovery.
- The term “knockout” refers to partial or complete suppression of the expression of at least a portion of a protein encoded by an endogenous DNA sequence in a cell. The term “knockout construct” refers to a nucleic acid sequence that is designed to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell. The nucleic acid sequence used as the knockout construct is typically comprised of (1) DNA from some portion of the gene (exon sequence, intron sequence, and/or promoter sequence) to be suppressed and (2) a marker sequence used to detect the presence of the knockout construct in the cell. The knockout construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to prevent or interrupt transcription of the native DNA sequence. Such insertion usually occurs by homologous recombination (i.e., regions of the knockout construct that are homologous to endogenous DNA sequences hybridize to each other when the knockout construct is inserted into the cell and recombine so that the knockout construct is incorporated into the corresponding position of the endogenous DNA). The knockout construct nucleic acid sequence may comprise 1) a full or partial sequence of one or more exons and/or introns of the gene to be suppressed, 2) a full or partial promoter sequence of the gene to be suppressed, or 3) combinations thereof. Typically, the knockout construct is inserted into an embryonic stem cell (ES cell) and is integrated into the ES cell genomic DNA, usually by the process of homologous recombination. This ES cell is then injected into, and integrates with, the developing embryo.
- Generally, for homologous recombination, the DNA will be at least about 1 kilobase (kb) in length and preferably 3-4 kb in length, thereby providing sufficient complementary sequence for recombination when the knockout construct is introduced into the genomic DNA of the ES cell.
- A “knock-in” mammal is a mammal in which an endogenous gene is substituted with a heterologous gene or a modified variant of the endogenous gene (Roemer et al., 1991). Preferably, the heterologous gene is “knocked-in” to a locus of interest, for example into a gene that is the subject of evaluation of expression or function, thereby linking the heterologous gene expression to transcription from the appropriate promoter (in which case the gene may be a reporter gene; see Elefanty et al., 1998). This can be achieved by homologous recombination, transposon (Westphal and Leder, 1997), using mutant recombination sites (Araki et al., 1997) or PCR (Zhang and Henderson, 1998).
- The phrases “disruption of the gene” and “gene disruption” refer to insertion of a nucleic acid sequence into one region of the native DNA sequence (usually one or more exons) and/or the promoter region of a gene so as to decrease or prevent expression of that gene in the cell as compared to the wild-type or naturally occurring sequence of the gene. By way of example, a nucleic acid construct can be prepared containing a DNA sequence encoding an antibiotic resistance gene which is inserted into the DNA sequence that is complementary to the DNA sequence (promoter and/or coding region) to be disrupted. When this nucleic acid construct is then transfected into a cell, the construct will integrate into the genomic DNA. Thus, some progeny of the cell will no longer express the gene, or will express it at a decreased level, as the DNA is now disrupted by the antibiotic resistance gene.
- The term “heterologous” refers to a combination of elements not naturally occurring. For example, heterologous DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell. A heterologous expression regulatory element is a such an element operatively associated with a different gene than the one it is operatively associated with in nature. In the context of the present invention, an gene is heterologous to the recombinant vector DNA in which it is inserted for cloning or expression, and it is heterologous to a host cell containing such a vector, in which it is expressed, e.g., a CHO cell.
- The terms “mutant” and “mutation” mean any detectable change in genetic material, e.g. DNA, or any process, mechanism, or result of such a change. This includes gene mutations, in which the structure (e.g., DNA sequence) of a gene is altered, any gene or DNA arising from any mutation process, and any expression product (e.g., protein) expressed by a modified gene or DNA sequence. The term “variant” may also be used to indicate a modified or altered gene, DNA sequence, enzyme, cell, etc., i.e., any kind of mutant.
- “Sequence-conservative variants” of a polynucleotide sequence are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position.
- “Function-conservative variants” are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids with similar properties are well known in the art. For example, arginine, histidine and lysine are hydrophilic-basic amino acids and may be interchangeable. Similarly, isoleucine, a hydrophobic amino acid, may be replaced with leucine, methionine or valine. Such changes are expected to have little or no effect on the apparent molecular weight or isoelectric point of the protein or polypeptide. Amino acids other than those indicated as conserved may differ in a protein or enzyme so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A “function-conservative variant” also includes a polypeptide or enzyme which has at least 60% amino acid identity as determined by BLAST (Altschul, et al., 1990) or FASTA algorithms, preferably at least 75%, most preferably at least 85%, and even more preferably at least 90%, and which has the same or substantially similar properties or functions as the native or parent protein or enzyme to which it is compared.
- An “ortholog” to a protein means a corresponding protein from another species. Orthologous proteins typically have similar functions in different species, and can also be substantially homologous.
- As used herein, the term “homologous” in all its grammatical forms and spelling variations refers to the relationship between proteins that possess a “common evolutionary origin,” including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck et al., 1987). Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity or the presence of specific residues or motifs. Motif analysis can be performed using, for example, the program BLOCKS (blocks.fhcrc.org on the World-Wide Web).
- Accordingly, the term “sequence similarity” in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin (see Reeck et al., supra). However, in common usage and in the instant application, the term “homologous,” when modified with an adverb such as “highly,” may refer to sequence similarity and may or may not relate to a common evolutionary origin.
- In a specific embodiment, two DNA sequences are “substantially homologous” or “substantially similar” when at least about 80%, and most preferably at least about 90 or 95% of the nucleotides match over the defined length of the DNA sequences, as determined by sequence comparison algorithms, such as BLAST, FASTA, DNA Strider, etc. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system.
- Similarly, in a particular embodiment, two amino acid sequences are “substantially homologous” or “substantially similar” when greater than 80% of the amino acids are identical, or greater than about 90% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wis.) pileup program, ProteinPredict (dodo.cmpc.columbia.edu/predictprotein on the World-Wide Web), or any of the programs described above (BLAST, FASTA, etc.).
- A nucleic acid molecule is “hybridizable” to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strenght (see Sambrook et al., supra). The conditions of temperature and ionic strength determine the “stringency” of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a Tm (melting temperature) of 55° C., can be used. Moderate stringency hybridization conditions correspond to a higher Tm and high stringency hybridization conditions correspond to the highest Tm. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher Tm) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating Tm have been derived (see Sambrook et al., supra, 9.50-9.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., supra, 11.7-11.8). A minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.
- The present invention provides antisense nucleic acids (including ribozymes), which may be used to inhibit expression of PAMP, e.g., to disrupt a cellular process (such disruption can be used in an animal model or therapeutically). An “antisense nucleic acid” is a single stranded nucleic acid molecule which, on hybridizing under cytoplasmic conditions with complementary bases in an RNA or DNA molecule, inhibits the latter's role. If the RNA is a messenger RNA transcript, the antisense nucleic acid is a counter transcript or mRNA-interfering complementary nucleic acid. As presently used, “antisense” broadly includes RNA-RNA interactions, RNA-DNA interactions, ribozymes and RNase-H mediated arrest. Antisense nucleic acid molecules can be encoded by a recombinant gene for expression in a cell (e.g., U.S. Pat. No. 5,814,500; U.S. Pat. No. 5,811,234), or alternatively they can be prepared synthetically (e.g., U.S. Pat. No. 5,780,607).
- As used herein, the term “oligonucleotide” refers to a nucleic acid, generally of at least 10, preferably at least 15, and more preferably at least 20 nucleotides, preferably no more than 100 nucleotides, that is hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene, mRNA, cDNA, or other nucleic acid of interest. Oligonucleotides can be labeled, e.g., with 32P-nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid. In another embodiment, oligonucleotides (one or both of which may be labeled) can be used as PCR primers, e.g. for cloning full length or a fragment of a protein or polypeptide. In a further embodiment, an oligonucleotide of the invention can form a triple helix with a nucleic acid (genomic DNA or mRNA) encoding a protein or polypeptide. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer. Accordingly, oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc. Furthermore, the oligonucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.
- Specific non-limiting examples of synthetic oligonucleotides envisioned for this invention include oligonucleotides that contain phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl, or cycloalkl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are those with CH2—NH—O—CH2, CH2—N(CH3)—O—CH2, CH2—O—N(CH3)—CH2, CH2—N(CH3)—N(CH3)—CH2 and O—N(CH3)—CH2—CH2 backbones (where phosphodiester is O—PO2—O—CH2). U.S. Pat. No. 5,677,437 describes heteroaromatic olignucleotide linkages. Nitrogen linkers or groups containing nitrogen can also be used to prepare oligonucleotide mimics (U.S. Pat. No. 5,792,844 and U.S. Pat. No. 5,783,682). U.S. Pat. No. 5,637,684 describes phosphoramidate and phosphorothioamidate oligomeric compounds. Also envisioned are oligonucleotides having morpholino backbone structures (U.S. Pat. No. 5,034,506). In other embodiments, such as the peptide-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al., 1991). Other synthetic oligonucleotides may contain substituted sugar moieties comprising one of the following at the 2′ position: OH, SH, SCH3, F, OCN, O(CH2)nNH2 or O(CH2)nCH3 where n is from 1 to about 10; C1 to C10 lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF3; OCF3; O—; S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH3; SO2CH3; ONO2; NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; a fluorescein moiety; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Oligonucleotides may also have sugar mimetics such as cyclobutyls or other carbocyclics in place of the pentofuranosyl group. Nucleotide units having nucleosides other than adenosine, cytidine, guanosine, thymidine and uridine, such as inosine, may be used in an oligonucleotide molecule.
- The presenilin genes (PS1-PS1 and PS2-PS2) encode homologous polytopic transmembrane proteins that are expressed at low levels in intracellular membranes including the nuclear envelope, the endoplasmic reticulum, the Golgi apparatus and some as yet uncharacterized intracytoplasmic vesicles in many different cell types including neuronal and non-neuronal cells (see U.S. application Ser. No. 08/431,048, filed Apr. 28, 1995; 08/496,841, filed Jun. 28, 1995; and 08/509,359, filed Jul. 31, 1995; PCT Publication No. WO 96/34099, and U.S. Pat. Nos. 5,986,054, 5,040,540, and 6,020,143, the disclosures of which are specifically incorporated herein by reference; Sherrington et al., 1995; Rogaev et al., 1995; Levy-Lahad et al., 1995; Doan et al., 1996; Walter et al., 1996; De Strooper et al., 1997; Lehmann et al., 1997; Li et al., 1997). Structural studies predict that the presenilins contain between six and eight transmembrane (TM) domains organized such that the N-terminus, the C-terminus, and a large hydrophilic loop following the sixth TM domain are located in the cytoplasm or nucleoplasm, while the hydrophilic loop between TM1 and TM2 is located within the lumen of membranous intracellular organelles (Doan et al., 1996; De Strooper et al., 1997; Lehmann et al., 1997).
- Proteins that interact with the presenilins, i.e., PS-interacting-protein elude PAMP, the S5a subunit of the 26S proteasome (GenBank; Accession No. U51007), Rab11 (GenBank; Accession Nos. X56740 and X53143), retinoid X receptor B, also known as nuclear receptor co-regulator or MHC (GenBank Accession Nos. M84820, and X63522), GT24 (GenBank Accession No. U81004), β-catenin (Zhou et al., 1997, and Yu et al., supra) as well as armadillo proteins. These and other PS1 binding proteins are described in Applicants' copending commonly assigned U.S. application Ser. No. 08/888,077, filed Jul. 3, 1997, as well as U.S. application Ser. No. 08/592,541, filed Jan. 26, 1996, and U.S. application Ser. No. 09/541,094, filed Mar. 31, 2000, the disclosures of which are incorporated herein by reference.
- PS1 and PS2 interact specifically with at least two members of the armadillo family of proteins; neuronal plakophilin-related armadillo protein (Paffenholtz et al., 1997; Paffenholtz et al., 1999; Zhou et al. (2), 1997) and β-catenin, that are expressed in both embryonic and post-natal tissues. Moreover, the domains of PS1 and PS2 that interact with these proteins have been identified. Mutations in PS1 and PS2 affect the translocation of β-catenin into the nucleus of both native cells and cells transfected with a mutant PS gene. These interactions and effects are described in detail in co-pending commonly assigned U.S. application Ser. No. 09/227,725, filed Jan. 8, 1999, the disclosure of which is incorporated herein by reference.
- The methods of the present invention are not limited to mutant presenilins wherein the PAMP-interacting domain is mutated relative to the wild-type protein. For example, Applicants have observed that mutations in PS1 (e.g., M146L) outside of the interacting domain (loop) also affect β-catenin translocation. These mutations probably disturb the presenilin armadillo interactions by altering the function of a high MW complex which contains, e.g., the presenilin and armadillo proteins, as described in Yu et al., 1998. Moreover, a comparison of the human PS1 (hPS1) and PS2 (hPS2) sequences reveals that these pathogenic mutations are in regions of the PS1 protein which are conserved in the PS2 protein. Therefore, corresponding mutations in corresponding regions of PS2 may also be expected to be pathogenic and are useful in the methods described herein.
- Mutant PS1 and PS2 genes, and their corresponding amino acid sequences are described in Applicants' co-pending U.S. application Ser. No. 08/888,077, filed Jul. 3, 1997, and incorporated herein by reference. Examples of PS1 mutations include I143T, M146L, L171P, F177S, A260V, C263R, P264L, P267S, E280A, E280G, A285V, L286V, A291-319, L322V, G384A, L392V, C410Y and I439V. Examples of PS2 mutations include N141I, M239V and I420T.
- PAMP mutants may cause biochemical changes similar to those affecting the onset or progression of schizophrenia. Therefore, artificial PAMP mutations can potentially be used to generate cellular and other model systems to design treatments and preventive strategies for schizophrenia and related disorders. Such mutations may also be used for evaluating whether PAMP is involved in the pathogenesis of schizophrenia. Since the amyloid-β (Aβ) inducing mutations are found in amino acid residues of a soluble (non-membrane spanning) domain of PAMP, analysis of the normal structure of this domain and the effects of these and other nearby mutations on the structure of this domain (and the other domains of PAMP) provide information for the design of specific molecular therapeutics.
- In general, modifications of the sequences encoding the polypeptides described herein may be readily accomplished by standard techniques such as chemical syntheses and site-directed mutagenesis. See Gillman et al., 1979; Roberts et al., 1987; and Innis, 1990. Most modifications are evaluated by routine screening via an assay designed to select for the desired property.
- According to the invention, PAMP polypeptides produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins and PAMP mutants, may be used as an immunogen to generate antibodies that recognize the PAMP polypeptide. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Such an antibody is preferably specific for human PAMP, PAMP originating from other species, or for post-translationally modified (e.g. phosphorylated, glycosylated) PAMP.
- Various procedures known in the art may be used for the production of polyclonal antibodies to PAMP polypeptide or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with the PAMP polypeptide, or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the PAMP polypeptide or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Antisera may be collected at a chosen time point after immunization, and purified as desired.
- For preparation of monoclonal antibodies directed toward the PAMP polypeptide, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Köhler and Milstein, 1975, as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983; Cote et al., 1983), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985). Production of human antibodies by CDR grafting is described in U.S. Pat. Nos. 5,585,089, 5,693,761, and 5,693,762 to Queen et al., and also in U.S. Pat. No. 5,225,539 to Winter and International Patent Application PCT/WO91/09967 by Adau et al. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (International Patent Publication No. WO 89/12690, published 28 Dec. 1989). In fact, according to the invention, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984); Neuberger et al., 1984; Takeda et al., 1985) by splicing the genes from a mouse antibody molecule specific for an PAMP polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described infra), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.
- According to the invention, techniques described for the production of single chain antibodies (U.S. Pat. Nos. 5,476,786 and 5,132,405 to Huston; U.S. Pat. No. 4,946,778) can be adapted to produce PAMP polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an PAMP polypeptide, or its derivatives, or analogs.
- Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab′)2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab′ fragments which can be generated by reducing the disulfide bridges of the F(ab′)2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
- In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), “sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of an PAMP polypeptide, one may assay generated hybridomas for a product which binds to an PAMP polypeptide fragment containing such epitope. For selection of an antibody specific to an PAMP polypeptide from a particular species of animal, one can select on the basis of positive binding with PAMP polypeptide expressed by or isolated from cells of that species of animal.
- The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the PAMP polypeptide, e.g., for Western blotting, imaging PAMP polypeptide in situ, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned above or known in the art. Such antibodies can be used to identify proteins that interact with PAMP, and to detect conformational or structural changes in PAMP.
- In a specific embodiment, antibodies that agonize or antagonize the activity of PAMP polypeptide can be generated. They can also be used to regulate or inhibit PAMP activity intracellular, i.e., the invention contemplates an intracellular antibody (intrabody), e.g., single chain Fv antibodies (see generally, Chen, 1997; Spitz et al., 1996; Indolfi et al., 1996; Kijima et al., 1995).
- The nucleotide sequence and the protein sequence and the putative biological activity of PAMP or PAMP mutants can all be used for the purposes of diagnosis of individuals who are at-risk for, or who actually have, a variety of neurodegenerative diseases (including Alzheimer's disease, Lewy body variant, Parkinson's disease-dementia complex, amyotrophic lateral sclerosis etc.), neuropsychiatric diseases (schizophrenia, depression, mild cognitive impairment, benign senescent forgetfulness, age-associated memory loss, etc.), neurodevelopmental disorders associated with defects in intracellular signal transduction mediated by factors such as Notch, Delta, Wingless, etc., and neoplasms (e.g., bowel cancer, etc.) associated with abnormalities of PS1/PAMP/PS2 mediated regulation of cell death pathways. These diagnostic entities can be used by searching for alterations in: the nucleotide sequence of PAMP; in the transcriptional activity of PAMP; in the protein level as monitored by immunological means (e.g. ELISA and Western blots); in the amino acid sequence (as ascertained by Western blotting, amino acid sequence analysis, mass spectroscopy); and/or in the biological activity of the PAMP protein as measured by either in vivo methods (e.g., monitoring βAPP processing and the production of amyloid-β peptide (Aβ), or other suitable protein substrates for PAMP including Notch, etc.), or by in vitro assays (using either whole cell or cell-free assays to measure processing of suitable substrate including βAPP or parts thereof, and other proteins such as Notch). Any of these assays can also be performed in a transgenic animal model as well, e.g., to measure the effect of a drug or a mutation or overexpression of a different gene in vivo.
- Identification and isolation of PAMP provides for development of screening assays, particularly for high throughput screening of molecules that up- or down-regulate the activity of PAMP, e.g., by permitting expression of PAMP in quantities greater than can be isolated from natural sources, or in indicator cells that are specially engineered to indicate the activity of PAMP expressed after transfection or transformation of the cells. Any screening technique known in the art can be used to screen for PAMP agonists or antagonists. The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to and agonize or antagonize the activity of PAMP in vivo. For example, natural products libraries can be screened using assays of the invention for molecules that agonize or antagonize PAMP activity.
- Another approach uses recombinant bacteriophage to produce large libraries. Using the “phage method” (Scott and Smith, 1990; Cwirla, et al, 1990; Devlin et al., 1990), very large libraries can be constructed (106-108 chemical entities). A second approach uses primarily chemical methods, of which the Geysen method (Geysen et al., 1986; Geysen et al., 1987; and the method of Fodor et al. (1991) are examples. Furka et al., 1988, Furka, 1991, Houghton (U.S. Pat. No. 4,631,211) and Rutter et al. (U.S. Pat. No. 5,010,175) describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.
- In another aspect, synthetic libraries (Needels et al., 1993; Ohlmeyer et al., 1993; Lam et al., WO 92/00252; Kocis et al., WO 9428028) and the like can be used to screen for PAMP ligands according to the present invention.
- Knowledge of the primary sequence of the protein, and the similarity of that sequence with proteins of known function, can provide an initial clue as to the inhibitors or antagonists of the protein. As noted above, identification and screening of antagonists is further facilitated by determining structural features of the protein, e.g., using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination. These techniques provide for the rational design or identification of agonists and antagonists.
- The PAMP protein sequence (including parts thereof) can be used to deduce the structural organization and topology of PAMP through the use of a variety of techniques including CD spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and molecular modeling. Sequences for PAMP or PAMP mutants can also be used to identify proteins which interact with PAMP either in concert with PS1 and PS2, or independently, using a variety of methods including co-immunoprecipitation, yeast two hybrid interaction trap assays, yeast three hybrid interaction trap assays, chemical cross-linking and co-precipitation studies, etc. These and other methods are described more fully in co-pending and commonly assigned U.S. application Ser. No. 08/888,077, filed Jul. 3, 1997, and 09/227,725, filed Jan. 8, 1999, both of which are incorporated herein by reference. Identification of these interacting partners will then lead to their use to further delineate the biochemical pathways leading to the above-mentioned diseases.
- Finally, the structural analysis of PAMP, when combined with structural analysis of PS1 and PS2, and other proteins which interact with PAMP or PAMP mutants, will identify the structural domains that mediate interactions between these molecules and which also confer biological activity on PAMP (or PAMP and these other molecules). These structural domains, and other functional domains, which can modulate the activity of these structural domains, can all be modified through a variety of means, including but not limited to site-directed mutagenesis, in order to either augment or reduce the biological activity. The structure and topology of these domains can all be used as a basis for the rational design of pharmaceuticals (small molecule conventional drugs or novel carbohydrate, lipid, DNA/RNA or protein-based high molecular weight biological compounds) to modulate (increase or decrease) the activity of PAMP and/or the PAMP PS1/PS2 complex, and/or the activity of the PAMP/other protein complexes. For example, using structural prediction calculations, possibly in conjunction with spectroscopic data like nuclear magnetic resonance, circular dichroism, and other physical-chemical structural data, or crystallographic data, or both, one can generate molecular models for the structure of PAMP. These models, in turn, are important for rational drug design. Drug candidates generated using a rational drug design program can then be applied for the treatment and/or prevention of the above-mentioned diseases, and can be administered through a variety of means including: as conventional small molecules through enteral or parenteral routes; via inclusion in liposome vehicles; through infusion in pumps inserted into various organs (e.g., via Omaya pumps inserted into the cerebral ventricles); via the transplantation of genetically-modified cells expressing recombinant genes; or via the use of biological vectors (e.g., retrovirus, adenovirus, adeno-associated virus, Lentivirus, or herpes simplex virus-based vectors) which allow targeted expression of appropriately modified gene products in selected cell types. It should be noted that the recombinant proteins described above may be the wild-type PAMP, a genetically-modified PAMP, a wild-type PS1/PS2, a genetically-modified PS1/PS2, or a specially-designed protein or peptide which is designed to interact with either the functional domains of PAMP (or the PAMP/
PS 1/PS2/other protein complex) or to interact with the domains which modulate the activity of the functional domains of PAMP. - The PAMP nucleotide sequence can be used to make cell-free systems, transfected cell lines, and animal models (invertebrate or vertebrate) of the neurodegenerative and other diseases outlined above. These animal and cell models may involve over-expression of all or part of PAMP or PAMP mutants, e.g., as mini-gene cDNA transgene constructs under the regulation of suitable promoter elements carried in vectors such as cos-Tet for transgenic mice and pcDNA (Invitrogen, California) in transfected cell lines. Animal and cellular models can also be generated by via homologous recombination mediated targeting of the endogenous gene to create artificially mutant sequences (knock-in gene targeting); or loss of function mutations (knock-out gene targeting); by translocation of P-elements; and by chemical mutagenesis. Animal, cellular and cell-free model systems can be used for a variety of purposes including the discovery of diagnostics and therapeutics for this disease.
- Included within the scope of this invention is a mammal in which two or more genes have been knocked out or knocked in, or both. Such mammals can be generated by repeating the procedures set forth herein for generating each knockout construct, or by breeding to mammals, each with a single gene knocked out, to each other, and screening for those with the double knockout genotype.
- Regulated knockout animals can be prepared using various systems, such as the tet-repressor system (see U.S. Pat. No. 5,654,168) or the Cre-Lox system (see U.S. Pat. No. 4,959,317 and No. 5,801,030).
- Transgenic mammals can be prepared for evaluating the molecular mechanisms of PAMP, and particularly human PAMP function. Such mammals provide excellent models for screening or testing drug candidates. It is possible to evaluate compounds or diseases on “knockout” animals, e.g., to identify a compound that can compensate for a defect in PAMP activity. Alternatively, PAMP (or mutant PAMP), alone or in combination with βAPP, PS1, PS2, and/or Notch, or some other component (double or triple transgenics) “knock-in” mammals can be prepared for evaluating the molecular biology of this system in greater detail than is possible with human subjects. Both technologies permit manipulation of single units of genetic information in their natural position in a cell genome and to examine the results of that manipulation in the background of a terminally differentiated organism. These animals can be evaluated for levels of mRNA or protein expression, processing of βAPP, or development of a condition indicative of inappropriate gene expression, e.g., Notch phenotype or another phenotype as set forth above, or neurodegeneration, including cognitive deficits, learning or memory deficits, or neuromuscular deficits.
- Various transgenic animal systems have been developed. Mice, rats, hamsters, and other rodents are popular, particularly for drug testing, because large numbers of transgenic animals can be bred economically and rapidly. Larger animals, including sheep, goats, pigs, and cows, have been made transgenic as well. Transgenic D. melanogaster and C. elegans can also be made and, using known genetic methods, may offer the ability to identify upstream and downstream modifiers of a PAMP phenotype. Transgenic animals can also be prepared by introducing the transgene on a vector; such animals, which are not modified in the germ line and are only transiently transgenic, naturally cannot pass along the genetic information to their progeny.
- In another series of embodiments, transgenic animals are created in which (i) a human PAMP, or a mutant human PAMP, is stably inserted into the genome of the transgenic animal; and/or (ii) the endogenous PAMP genes are inactivated and replaced with their human counterparts. See, e.g., Coffman, 1997; Esther et al., 1996; Murakami et al, 1996. Such animals can be treated with candidate compounds and monitored for the effects of such drugs on PAMP cavity.
- As discussed above, abnormalities in PAMP expression and/or interactions with PS1/PS2/βAPP are associated with severe neurological deficits. Thus, the present invention provides for treatment of such deficits either with a drug discovered using a screening assay or transgenic animal model, or both, as set forth above, or by replacing a defective PAMP gene with a functional gene by gene therapy.
- A gene encoding PAMP, a PAMP mutant, or alternatively a negative regulator of PAMP such as an antisense nucleic acid, intracellular antibody (intrabody), or dominant negative PAMP (which may be truncated), can be introduced in vivo, ex vivo, or in vitro using a viral or a non-viral vector, e.g., as discussed above. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both. Targeted gene delivery is described in WO 95/28494, published October 1995.
- Preferably, for in vivo administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, e.g., adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin 12 (IL 12), interferon-γ (IFNγ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors (see, e.g., Wilson, 1995). In that regard, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.
- Herpes virus vectors. Because herpes virus is trophic for cells of the nervous system (neural cells), it is an attractive vector for delivery of function PAMP genes. Various defective (non-replicating, and thus non-infectious) herpes virus vectors have been described, such as a defective herpes virus 1 (HSV 1) vector (Kaplitt et al., 1991; International Patent Publication No. WO 94/21807, published Sep. 29, 1994; International Patent Publication No. WO 92/05263, published Apr. 2, 1994).
- Adenovirus vectors. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types in vivo, and has been used extensively in gene therapy protocols, including for targeting genes to neural cells. Various serotypes of adenovirus exist. Of these serotypes, preference is given to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard et al., 1990), ovine, porcine, avian, and simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g., Manhattan or A26/61 strain (ATCC VR-800), for example). Various replication defective adenovirus and minimum adenovirus vectors have been described for gene therapy (WO94/26914, WO95/02697, WO94/28938, WO94/28152, WO94/12649, WO95/02697 WO96/22378). The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero et al., 1991; EP 185 573; Graham, 1984; Graham et al., 1977). Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.
- Adeno-associated viruses. The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterized. The use of vectors derived from the AAVs for transferring genes in vitro and in vivo has been described (see WO 91/18088; WO 93/09239; U.S. Pat. No. 4,797,368, U.S. Pat. No. 5,139,941, EP 488528). The replication defective recombinant AAVs according to the invention can be prepared by co-transfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line which is infected with a human helper virus (for example an adenovirus). The AAV recombinants which are produced are then purified by standard techniques.
- Retrovirus vectors. In another embodiment the gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Pat. No. 5,399,346; Mann et al., 1983; Temin et al., U.S. Pat. No. 4,650,764; Temin et al., U.S. Pat. No. 4,980,289; Markowitz et al. 1988; Temin et al., U.S. Pat. No. 5,124,263; EP 453242, EP178220; Bernstein et al., 1985; McCormick, 1985; International Patent Publication No. WO 95/07358, published Mar. 16, 1995, by Dougherty et al.; and Kuo et al., 1993. The retroviruses are integrating viruses which infect dividing cells. The retrovirus genome includes two LTRs, an encapsidation sequence and three coding regions (gag, pol and env). In recombinant retroviral vectors, the gag, pol and env genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus, such as MoMuLV (“murine Moloney leukemia virus”), MEV (“murine Moloney sarcoma virus”), HASV (“Harvey sarcoma virus”); SNV (“spleen necrosis virus”), RSV (“Rous sarcoma virus”) and Friend virus. Suitable packaging cell lines have been described in the prior art, in particular the cell line PA317 (U.S. Pat. No. 4,861,719); the PsiCRIP cell line (WO 90/02806) and the GP+envAm-12 cell line (WO 89/07150). In addition, the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsidation sequences which may include a part of the gag gene (Bender et al., 1987). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.
- Retrovirus vectors can also be introduced by recombinant DNA viruses, which permits one cycle of retroviral replication and amplifies transfection efficiency (see WO 95/22617, WO 95/26411, WO 96/39036, WO 97/19182).
- Lentivirus vectors. In another embodiment, lentiviral vectors are can be used as agents for the direct delivery and sustained expression of a transgene in several tissue types, including brain, retina, muscle, liver and blood. The vectors can efficiently transduce dividing and non-dividing cells in these tissues, and maintain long-term expression of the gene of interest. For a review, see, Naldini, 1998; see also Zufferey, et al., 1998). Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of high-titer lentivirus vectors for gene therapy. An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line which can generate virus particles at titers greater than 106 IU/ml for at least 3 to 4 days (Kafri, et al., 1999). The vector produced by the inducible cell line can be concentrated as needed for efficiently transducing nondividing cells in vitro and in vivo.
- Non-viral vectors. A vector can be introduced in vivo in a non-viral vector, e.g., by lipofection, with other transfection facilitating agents (peptides, polymers, etc.), or as naked DNA. Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection, with targeting in some instances (Felgner, et. al., 1987; Felgner and Ringold, 1989; see Mackey, et al., 1988; Ulmer et al., 1993). Useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and WO96/17823, and in U.S. Pat. No. 5,459,127. Other molecules are also useful for facilitating transfection of a nucleic acid in vivo, such as a cationic oligopeptide (e.g., International Patent Publication WO95/21931), peptides derived from DNA binding proteins (e.g., International Patent Publication WO96/25508), or a cationic polymer (e.g., International Patent Publication WO95/21931). Recently, a relatively low voltage, high efficiency in vivo DNA transfer technique, termed electrotransfer, has been described (Mir et al., 1998; WO 99/01157; WO 99/01158; WO 99/01175). DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun (ballistic transfection), or use of a DNA vector transporter (see, e.g., Wu et al., 1992; Wu and Wu, 1988; Hartmut et al., Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990; Williams et al., 1991). Receptor-mediated DNA delivery approaches can also be used (Curiel et al., 1992; Wu and Wu, 1987). U.S. Pat. Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal.
- The present invention will be further understood by reference to the following examples, which are provided as exemplary of the invention and not by way of limitation.
- This example shows that both PS1 and PS2 interact with a novel Type I transmembrane protein, PAMP, and that this novel protein also interacts with α- and β-secretase derived fragments of βAPP. We also show that abolition of functional expression of the C. elegans homologue of the protein leads to a developmental phenotype (anterior pharynx aph-2) which is thought to be due to inhibition of the glp/Notch signaling pathway. This novel protein is therefore positioned to mediate both the gain of function and loss of function phenotypes associated with presenilin missense mutations and presenilin knockouts, respectively.
- Antibodies against PS1, PS2 and βAPP. An antibody, termed 1142, directed against PS1, was raised to a peptide segment corresponding to residues 30-45 of PS1 (Levesque et al., 1998; Yu et al., 1998). The peptide was synthesized by solid-phase techniques and purified by reverse phase high pressure liquid chromatography (HPLC). Peptide antigens were linked to keyhole limpet hemocyanin (KLH) and used, in combination with complete Freud's adjuvant, to innoculate New Zealand White rabbits. Antisera from three rabbits was pooled, ammonium precipitated and the antibody was purified with Sulfo-link (Pierce) agarose-peptide affinity columns. Other antibodies used include antibody 369, a polyclonal rabbit-anti-human antibody directed against the C-terminus of human βAPP (Buxbaum et al., 1990); antibody 14 (Ab 14), a rabbit polyclonal antibody raised against residues 1-25 of human PS1 (Seeger et al., 1997); antibody α-PS1-CTF, a polyclonal rabbit antibody directed against the PS1 loop; and antibody DT2, a monoclonal antibody raised to a GST-fusion protein containing the PS2 N-terminal sequence from residues 1-87.
- Preparation of presenilin associated components. To identify membrane associated components of the presenilin complex, an immunoaffinity procedure was used to extract PS1 and tightly associated membrane proteins from semi-purified intracellular membrane fractions. Human embryonic kidney cells (HEK) 293 (ATCC) with a stable over-expression of moderate level wild type human PS1, were grown to confluence, washed twice with ice-cold phosphate-buffered saline, and then homogenized with Buffer A (0.25 M sucrose, 20 mM HEPES pH 7.2, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and a protease inhibitor cocktail containing 5 mg/ml each of Leupeptin, Antipain, pepstatin A, Chymostatin, E64, Aprotinin, and 60 mg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF)). The cell homogenates were centrifuged 1000×g for 10 minutes to remove cell debris. The supernatant was then centrifuged 10,000×g for 60 minutes. The resulting membrane pellet was resuspended in Buffer B (20 mM HEPES pH 7.2, 1 M KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitor cocktail as above) and incubated for 45 minutes with agitation at 4° C. Cell membranes were collected again by centrifugation at 107,000×g for 60 minutes. The cell membranes were then lysed on ice for 60 minutes with Buffer C (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitors cocktail). After spinning 10,000×g for 15 minutes, the protein extract was adjusted with Buffer C to contain 5 mg/ml protein. A total of 0.5 g of protein was obtained.
- Isolation. The extracted proteins were then subjected to fractionation with 10-40% glycerol gradient containing 0.5% Digitonin as described (Yu et al., 1998). After being verified by Western blotting with anti-PS1 antibodies, the peak fractions containing PS1 were pooled and incubated overnight with Protein A/G agarose coupled with either antibody 1142 or a control IgG purified from preimmune rabbit serum. The Protein A/G agarose beads were washed three times with Buffer D (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, protease inhibitors cocktail), and three times with Buffer E (0.5% Digitonin, 0.5% CHAPS, 20 mM HEPES pH 7.2, 100 mM KCl, 10 mM CaCl2, 5 mM MgCl2, and the protease inhibitor cocktail as above). Isolated protein complexes were eluted from the beads with 0.1M Glycine-HCl, pH 3.0, and then neutralized with 1M Tris. Proteins were then separated by Tris-Glycine SDS-PAGE gels and stained with silver stain and Coomassie Blue stain. The staining of the immuno-purified proteins displayed two intense bands in addition to those of the presenilin holoprotein and its fragments.
- Sequence analysis. Individual protein bands were cut out and analyzed with solid-phase extraction capillary electrophoresis mass spectrometry/mass spectrometry (SPE-CE-MS/MS). Briefly, protein bands were first digested in gel with trypsin; the digested proteins were extracted and dried in a speed vacuum down to concentrate the peptides; and the peptides thereafter separated with micro LC and analyzed by on-line tandem mass spectrometry (Figeys et al., 1999). Nucleotide and amino acid sequence homology searches were conducted using the BLAST algorithm, and motif analyses performed using the program BLOCKS.
- General transfection and analysis methods. Based on the human PAMP sequence, public databases (e.g., GenBank; see ncbi.nlm.nih.gov on the World-Wide Web (www)) were searched for homologous ESTs (SEQ ID NOs: 3-10), which were collected into a few contigs. These contigs all turned out to be correct, but did not cover full-length mouse and D. melanogaster cDNAs.
- Full length murine (SEQ ID NO: 15), human (SEQ ID NO: 13) and D. melanogaster (SEQ ID NO: 17) PAMP cDNAs were obtained using oligonucleotides designed from partial cDNA/EST sequences in public databases to screen appropriate cDNA libraries, for 5′RACE, and/or for RT-PCR experiments. A PAMP expression construct was generated by inserting human PAMP cDNA in-frame with the V5 epitope of pcDNA6 (Invitrogen) at the C-terminus of PAMP. HEK293 cells with a stable expression of PS1/PS2 and βAPPsw were transiently transfected with either V5-tagged PAMP or empty plasmid (mock transfection control). Duplicate experiments were performed by: (1) transient transfection of V5-PAMP and βAPP695 (or empty vector plus βAPP695 as a mock transfection control) into murine embryonic fibroblasts stably infected with human PS1 expressed from a retroviral vector construct (Clontech, CA); or (2) transient transfection of V5-PAMP (or an empty plasmid) into HEK293 cell lines with a stable expression of the C-terminal 99 amino acids of βAPP with a preceding artificial signal peptide (spC100-APP) together with either wild type PS1, PS1-L392V, or PS1-D385A. Cells were lysed with a Digitonin lysis buffer or with 1% NP40, and the protein extracts were subjected to gradient fraction, immunoprecipitation or direct Western blotting as described (Yu et al., 1998). PS1 was immunodetected or immunoprecipitated with antibodies 14 or a-PS1-CTF; and PS2 was immunodetected or immunoprecipitated with antibody DT2. FL-βAPP and its C-terminal α- and β-secretase derivatives were detected using antibody 369.
- Isolation of PAMP. Immunoprecipitation of PS1 protein complexes, followed by SDS-PAGE with Coomassie Blue and silver staining, yielded two intense bands in addition to presenilin holoprotein. These bands were characterized by mass spectroscopy analysis. Mass spectroscopy analysis revealed several armadillo repeat containing peptides, (previously known to functionally interact with presenilins (Yu et al., 1998; Zhou et al. (1), 1997; Nishimura M, et al., 1999), and a novel peptide (PAMP) which had a sequence identified to that predicted for an anonymous, partial cDNA (Genbank; Accession No. D87442). The cDNA sequence predicted an open reading frame of 709 amino acids (SEQ ID NO: 14), which contains a putative N-terminal signal peptide, a long N-terminal hydrophilic domain with sequence motifs for glycosylation, N-myristoylation and phosphorylation, a ˜20 residue hydrophobic putative transmembrane domain, and a short hydrophilic C-terminus of 20 residues (
FIGS. 1A and 1B ). - Orthologous PAMP proteins. The PAMP amino acid sequence had no significant homology to other proteins within available databases, except for a hypothetical C. elegans protein (www.ncbi.nih.gov; Accession No. Q23316) (p=2×10−28; identity=22%; similarity=39%) (SEQ ID NO: 12) ascertained from a genomic DNA sequence (
FIGS. 1A and 1B ). In addition to strong primary amino acid sequence conservation, this C. elegans protein has a very similar topology to human PAMP, suggesting that it is the nematode orthologue of human PAMP. - In the absence of functional clues arising from homologies to other known proteins, the predicted amino acid sequences of the murine (SEQ ID NO: 16) and D. melanogaster (SEQ ID NO: 18) orthologues of PAMP were cloned and examined. The four orthologous PAMP proteins had a similar topology and significant sequence conservation near residues 306-360, 419-458, and 625-662 of human PAMP (SEQ ID NO: 14) (
FIGS. 1A and 1B ). Motif analysis of these conserved domains revealed a weak similarity (strength=1046) between residues 625-641 (ARLARALSPAFELSQWS; SEQ ID NO: 19) of mouse and human PAMP to cyclic nucleotide binding domains. While the putative transmembrane domain sequences were not highly conserved, all four orthologues contained a conserved serine residue within this hydrophobic domain. Finally, there were four conserved cysteine residues in the—terminal hydrophilic domain (Cys195, Cys213, Cys230, and Cys248 in human PAMP) which had a periodicity of 16-17 residues in the N-terminus, and may form a functional domain (e.g., a metal binding domain or disulfide bridges for stabilizing the tertiary structure of PAMP/PAMP complexes). - Interaction of PAMP with
presenilin 1. To confirm the authenticity of the PAMP:PS1 interaction, HEK293 cells were transiently transfected with PAMP cDNA (SEQ ID NO: 13) tagged at the 3′-end with a V5-epitope encoded from the pcDNA6 vector. The conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the Aβ40 and Aβ42 levels were measured by ELISA (Zhang L, et al., 1999). In Western blots of lysates of these cells, the use of anti-V5 (Invitrogen, CA) and enhanced chemiluminescence (Amersham) detected a V5-immunoreactive band of ˜110 kDa which was reduced to ˜80 kDa following Endo H digestion (equivalent to the size predicted from the PAMP amino acid sequence), confirming the predicted glycosylation of PAMP. In addition, a series of about 7-10 kDa fragments were observed, which are predicted to contain the TM domain and short C-terminus of PAMP plus the 3 kDa V5-epitope. These C-terminal derivatives may be authentic cleavage products of full-length PAMP, or, alternatively, a proteolytic artifact arising from the attachment of the V5-epitope to the C-terminus of PAMP. - Reciprocal immunoprecipitation studies in cells expressing combinations of transfected V5-tagged-PAMP, transfected wild type or mutant PS1, transfected wild type PS2, or endogenous presenilins, confirmed the PS1:PAMP interaction, and showed a similar interaction between PAMP and PS2. In contrast, immunoprecipitation of other ER-resident proteins (e.g., calnexin) failed to show any evidence of an interaction between these proteins and PAMP. Glycerol velocity gradient analysis of the native conformation of PAMP revealed that PAMP was co-eluted into the same high molecular weight fractions as PS1 and PS2, indicating that it is an authentic component of the high molecular weight presenilin protein complexes. These biochemical data were supported by immunocytochemical studies, which showed that transfected PAMP and endogenous PS1 strongly co-localized in the ER and Golgi in MDCK canine kidney/epithelial cells (ATCC). Similar studies with PS2 confirmed that PAMP also tightly associates with both endogenous PS2 in human brain and with transfected PS2 in HEK293 cells.
- The PAMP gene. Chromosomal locations and genetic map positions of the murine and human PAMPS were obtained from public genetic and transcriptional maps (www.ncbi.nlm.nih.gov). The gene encoding PAMP is located on
human chromosome 1 near the genetic markers D151595 and D1S2844. The 5′-end of the PAMP gene is embedded in the 5′-end of the coatmer gene encoded on the opposite strand. The human PAMP gene is close to a cluster of markers which have yielded positive, but sub-significant evidence for linkage to or association with Alzheimer Disease in two independent genome wide surveys (Kehoe et al., 1999). The murine PAMP maps within a 700 Kb interval ofmurine chromosome 1 which contains the gene defect associated with Looptail phenotype in mice (Underhill et al., 1999). Mice heterozygous for Looptail show developmental defects in dorsal axial structures including notochord, brain, spinal cord, and somites (Greene et al., 1998), which are reminiscent of those observed in PS1−/− mice (Shen J, et al., 1997; Wong et al., 1997). These observations suggest that the presenilin: PAMP complex may be involved in both βAPP and Notch processing. - C. elegans homolog of PAMP. The C. elegans homolog of PAMP corresponds to the aph-2 gene. Mutations in aph-2 have been identified in a screen for mutants with phenotypes identical to embryonic mutant phenotypes caused by loss of glp-1 activity, i.e., lack of an anterior pharynx, e.g. cDNA clone. The EST corresponding to aph-2, (cDNA clone yk477b8, kindly provided by Y. Kohara, National Institute of Genetics, Japan) was sequenced and the coding region (SEQ ID NO: 11) found to match exactly the Genefinder prediction made by the C. elegans sequencing consortium (Genbank; Accession No. Z75714). Double stranded RNA interference (RNAi) confirmed the mutant phenotype of aph-2. Sense and antisense RNA were transcribed in vitro from PCR product amplified from the phage yk477b8. After annealing equal quantities of sense and antisense products, the dsRNA product made was injected into L4 stage wild-type worms. The chosen line of worms, designated lin-12(n302) (Greenwald and Seydoux, 1990; Greenwald, et al., 1983) was obtained from the Caenorhabditis Genetics Center. Injected animals were transferred to fresh plates daily and the progeny scored at least 36 hours after injection for the embryonic lethal phenotype and 4-5 days after injection for the egg-laying phenotypes. Animals injected with dsRNA from yk477b8 template produced eggs that lacked an anterior pharynx. These results support the notion that aph-2/PAMP contributes to cell interactions mediated by glp-1/Notch in the embryo.
- Functional role for the PAMP:presenilin complexes in βAPP processing. To examine a functional role for the PAMP:presenilin complexes in βAPP processing, the interactions between PAMP, PS1, and βAPP, and its derivatives were investigated. The cell lines used were transiently transfected with V5-tagged PAMP, and stably expressing wild type βAPP695 in addition to wild type PS1, wild type PS2, PS1-L392V mutant, or PS1-D385A mutant. The PS1-L392V mutation is a pathogenic mutation associated with familial AD (Sherrington et al., 1995) and with increased secretion of Aβ42 (Scheuner et al., 1996; Citron et al., 1997). The PS1-D385A mutation is a loss of function mutation associated with inhibition of PS1 endoproteolysis and a decrease in γ-secretase activity (Wolfe et al., 1999). The conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the Aβ40 and Aβ42 levels were measured by ELISA (Zhang et al., 1999). Analysis of Western blots from these co-immunoprecipitation experiments revealed that PAMP holoprotein (and C-terminally tagged proteolytic fragments of PAMP) interacted in equivalent degrees with wild type PS1, wild type PS2, PS1-L392V mutant, and PS1-D385A mutant proteins. In addition, PAMP holoprotein and the C-terminal proteolytic fragments of PAMP also co-immunoprecipitated with the C-terminal proteolytic fragments of βAPP but not βAPP holoprotein in lysates of cells expressing either βAPP holoprotein or just the C-terminal 99 amino acids of βAPP. Significantly, compared to cells expressing equivalent quantities of wild type PS1, cell lines expressing pathogenic mutations of PS1 showed increased amounts of C-terminal βAPP fragments co-immunoprecipitating with PAMP. Conversely, cell lines expressing the loss-of-function PS1-D385A mutation showed greatly reduced amounts of C-terminal βAPP derivatives co-immunoprecipitating with PAMP despite the presence of very large amounts of C-terminal βAPP derivatives in these cells.
- These results were confirmed in HEK293 cells over-expressing either βAPPSwedish or the SpC99-βAPP cDNA. The latter encodes the C-terminal 99 residues of βAPP (corresponding to the products of β-secretase cleavage) plus the βAPP signal peptide. The interaction of PAMP appears much stronger with C99-βAPP than that with C83-βAPP. However, C83-βAPP is much less abundant in these cells (
FIG. 6 b, middle panel, lanes 1-4). In fact, PAMP does interact with both C99- and C83-βAPP stubs (seeFIG. 6 c, lane 9 andFIG. 8 d). Cumulatively, these results indicate that PAMP likely interacts with the C-terminal derivatives of βAPP which are the immediate precursors of Aβ and p3. However, of greater interest, the genotype of the co-expressed PS1 molecule dynamically influenced the interaction between PAMP and C99-/C83-βAPP stubs. Thus, more C-terminal βAPP fragments co-immunoprecipitated with PAMP in cells expressing the FAD-associated PS1-L392V mutation compared to cells expressing wild type PS1 (and equivalent quantities of nicastrin and C9-βAPP). Conversely, much less C terminal βAPP derivatives co-immunoprecipitated with PAMP in cell lines expressing the loss-of-function PS1-D385A mutation (despite the presence of very large amounts of C-terminal βAPP derivatives in these cells). These effects are more easily seen in cells over-expressing the C99-βAPP construct. However, similar but less pronounced differences were also observed in cells over-expressing full-length βAPPSwedish. More importantly, the PS1-sequence-related differences in the interaction of PAMP with C-terminal βAPP derivatives were most evident within 24 hours of transient transfection of PAMP. By 72 hours, the PS1-sequence-related differences were largely abolished. This dynamic change in the interaction of PAMP with C99/C83-βAPP was not due to changes in the levels of PS1, C-terminal βAPP derivatives or PAMP. One interpretation of these results is that the presenilins may be dynamically involved in regulating or loading PAMP with the substrates of γ-secretase. - Presenilin binding domains of PAMP. In transiently transfected cells (in which the 7-10 kDa C-terminal of PAMP can be detected), anti-PS1 immunoprecipitation products contain both full length PAMP and the 7-10 kDa C-terminal PAMP fragments. Similarly, in these cells, immunoprecipitation with antibodies to the C-terminus of βAPP (Ab369) also renders C-terminal nicastrin epitopes. The TM domain of PAMP is not highly conserved in evolution. These results suggest that the C99-/C83-βAPP and PS1/PS2-binding domain(s) of PAMP are in the TM domain or C-terminus.
- The above results indicate that PAMP is a component of the PS1 and PS2 intracellular complexes. The observations that PAMP also binds to the C-terminal fragment of βAPP (arising from α- and β-secretase cleavage of full length βAPP), that the degree of binding of these fragments to PAMP is modulated by mutations in PS1, and that the direction of this modulation is congruent with the effects of each mutant of Aβ production (i.e., the pathogenic L392V mutation increases binding to PAMP and increases Aβ42 production whereas the D385A mutation has the opposite effects) strongly argues that PAMP is part of a functional complex involved in processing of C-terminal βAPP derivatives. Similarly, the observation that inhibition of PAMP expression in C. elegans leads to a phenotype similar to that of glp/Notch loss of function, argues that PAMP, like PS1 and PS2, is also a functional component of the pathways involved in processing of Notch. This conclusion is strengthened by the fact that the murine PAMP gene maps within a 700 kb interval on
murine chromosome 1 which carries the Looptail mutant, and is thus likely to be the site of the Looptail mutation. Looptail has a number of phenotypic similarities to those of Notch and PS1 knockouts in mice. Because Looptail is a model of human spinal cord malformations including spina bifida, PAMP biology may also provide some useful insights into this neurological developmental defect as well. - At the current time the exact role of PAMP in the presenilin-complex-mediated processing of βAPP and Notch-like molecules is not fully defined. Inspection of the primary amino acid sequence of PAMP does not reveal very strong homologies to known proteases. However, the recombinant expression systems of the invention permit evaluation of three-dimensional structure of PAMP; it is possible that PAMP itself has a protease activity. However, it is currently more plausible that PAMP plays another role in βAPP and Notch processing. Thus, PAMP may be involved in the function of PS1 and PS2 complexes by binding substrates for γ-secretase. The efficacy of this binding is clearly modulated by PS1 mutations in a direction which is commensurate with the effect of these mutations on 7-secretase activity. Alternatively, PAMP may have a regulatory role on the activity of the presenilin complexes. This is consistent with the observation that residues 625-641 of human and murine PAMP contain a motif similar to cyclic nucleotide binding domains of several other unrelated proteins.
- Regardless of its precise role, it is clear that PAMP and PS1 both play important roles in γ-secretase mediated processing of βAPP. Hence, knowledge of PAMP and its biology will now serve as a target for efforts to manipulate the function of the presenilin complexes in patients with schizophrenia and/or Alzheimer Disease and related disorders, patients with malignancies (in which the presenilins have been implicated by virtue of a role in programmed cell death), and in disorders of development especially of the spinal cord and brain (in view of the known effects of PS1 knockout and the strong likelihood that PAMP is the site of Looptail mutations in mice). In particular, knowledge of the domains of PAMP involved in binding presenilins and βAPP derivatives (which currently appears to be located within the C-terminal transmembrane and hydrophilic domains of PAMP) and the identification of putative ligands interacting with the conserved domains at the hydrophilic N-terminus of PAMP will considerably expedite this goal.
- We have found that the strength of the interaction between PAMP and the C-terminal fragments of βAPP (which is the precursor Aβ) is determined by the genotype at PS1. Thus, clinical mutations in PS1 cause Alzheimer Disease and an increase in the production of Aβ42 are associated with increased binding of the C-terminal fragments of βAPP to PAMP. Conversely, loss of function mutations in PS1 (Asp385Ala) which inhibit γ-secretase cleavage of C-terminal fragments of βAPP, are associated with abolition of the interaction between PAMP and the C-terminal fragments of βAPP.
- Finally, the apparent C-terminal proteolytic derivatives of βAMP could either be authentic, or simply artifacts due to the V-5 tag. If they are authentic, this observation raises the possibility that PAMP may undergo post-translational processing events which are potentially similar to those of βAPP and/or Notch. Three observations support our discovery of PAMP. First, in contrast to βAPP and Notch, which are not major constituents of the high molecular weight presenilin complexes, and which can only be inconsistently shown to be directly associated with PS1/PS2, PAMP is a major stoichiometric component of the presenilin complexes. Second, PAMP selectively interacts only with C-terminal derivatives of βAPP which are substrates for γ-secretase cleavage, and this interaction is modulated by PS1 mutations in a way which reflects the functional consequences of these PS1 mutations. Third, inhibition of PAMP expression in C. elegans leads to a disease phenotype likely to be in the glp/Notch signaling pathway.
-
Site-directed mutagenesis was used to generate the following artificial mutations in PAMP: Cys: PAMPC230A in the 4 conserved cystine motif DYIGS: PAMPD336A/Y337A in the central conserved region D369L: PAMPΔ312-369 in the central conserved region D340X: PAMPΔ312-340 in the central conserved region YDT: PAMPD458A in the putative ‘aspartyl protease’ DTA site SPAF: PAMPD633A/F635A in the SPAF motif TM: PAMPS683A in the TM domain C3D: PAMPΔ630-668 in the conserved region adjacent to the TM domain - To further examine the role of PAMP in βAPP processing, we inserted PAMP cDNAs, harboring the above mutations as well as normal/wild type PAMP (PAMPwt) cDNA and the cDNA for an unrelated protein (LacZ), in frame into pcDNA6 vectors. A series of HEK293 cell lines stably expressing endogenous PS1, βAPPSwedish and either wild type PAMP or PAMP constructs in which various conserved domains had been mutated or deleted, were then created by transfection. PAMP expressing cells were selected with lasticidin to generate stable cell lines. Conditioned media from these cell lines were collected after 6-24 hours and Aβ40 and Aβ42 were measured by ELISA. In the PAMPD336A/Y337A mutant, both Aβ40 and Aβ42 levels were increased, and there was also a 68% increase in Aβ42/Aβ40 ratio which is very similar to that observed in clinical mutations in APP, PS1, and PS2, associated with early onset Alzheimer Disease. The Aβ42/Aβ40 ratio was also increased in one cell line expressing the PAMPC230A mutant.
- In contrast, both the total Aβ42 and Aβ40 levels and the Aβ42/Aβ40 ratio were massively reduced (to only 18% of the control) in the PAMPΔ312-369 mutant. A similar but less profound reduction of both the total Aβ42 and Aβ40 levels and the Aβ42/Aβ40 ratio was observed in the conditioned medium from the PAMPΔ312-340 cell lines.
- There is no apparent difference in Aβ42 or Aβ40 levels, or in the Aβ42/Aβ40 ratio, when the PAMPwt, PAMPD458A, PAMPΔ630-668, PAMPP633A/F635A, and PAMPS683A cells were compared to control lines (expressing LacZ, or empty vector).
- Thus, certain PAMP mutants cause biochemical changes similar to those induced by mutations in the βAPP, PS1, and PS2 genes which give rise to AD, and which may be implicated also in schizophrenia. These artificial PAMP mutations can therefore be used to generate cellular and other model systems to design treatments and preventions for schizophrenia, AD and other neurodegenerative and/or neuropsychiatric disorders. These mutations also show that PAMP is involved in the pathogenesis of AD, and may provide information for the design of specific molecular diagnostics or therapeutics for schizophrenia, AD, and other neurological disorders.
- When compared to mock-transfected or LacZ transfected cells, overexpression of wild type PAMP, and overexpression of most PAMP mutation- or deletion-constructs had no significant effect on Aβ secretion. However, missense mutation of the conserved DYIGS motif to AAIGS (residues 336-340 of human PAMP) caused a significant increase in Aβ42 secretion, a smaller increase in Aβ40 secretion, and an increase in the Aβ42/Aβ40 ratio (p<0.001; Table 2). This increase in Aβ42 production was equivalent to that of FAD-related missense mutations in PS1. Conversely, deletion of the DYIGS domain in two independent constructs (PAMPΔ312-369 and PAMPΔ312-340) caused a significant reduction in both Aβ42 and Aβ40 secretion which was more profound in PAMPΔ312-369 cells than in PAMPΔ312-340 cells (Table 2). The magnitude of the reduction in Aβ secretion in PAMPΔ312-369 cells was equivalent to that observed with the PS1-D385A loss-of-function mutation. Somewhat unexpectedly, and in contrast to PS1−/− and PS1-D385A cells, the reduction in Aβ secretion in NCTΔ312-369 and NCTΔ312-340 cells was not accompanied by the expected accumulation of C99- and C83-βAPP stubs. Since there was no consistent change in the levels of soluble βAPP (βAPPs) in the conditioned medium of any of the PAMP mutant cells, the most probable explanation for this result is that C99- and C83-βAPP stubs which do not enter the PAMP:presenilin complex for γ-secretase cleavage to Aβ may be degraded by other pathways.
- The effects of PAMP mutations on Aβ secretion were not due to trivial explanations such as differences in the levels of PAMP, βAPP holoprotein, or PS1/PS2. None of these mutations caused any consistent, detectable change in the amount of APPs in conditioned medium or in the amount of C99/C83-βAPP that could be co-immunoprecipitated with PAMP. However, both the PAMPΔ312-369 mutant and the PAMPΔ312-340 deletion mutant significantly reduced the amount of PS1 which could be co-immunoprecipitated with PAMP. Interestingly, the reduction in efficiency of binding to PS1 was proportional to the reduction in Aβ secretion induced by each deletion mutant. Multiple mechanisms underlying the effect of mutations in the first conserved domain can explain these results. This domain contains no obvious functional motifs (e.g., for glycosylation etc.), nor does it have significant sequence homology to other known proteins. Consequently, the three functionally active PAMP mutations either affect a presenilin-binding domain in PAMP, or affect a specific regulatory domain of PAMP which modulates both direct binding of PAMP to PS1 and the subsequent γ-secretase-mediated cleavage of PAMP-bound C99- and C83-βAPP stubs.
TABLE 2 Normalized Normalized Aβ42/Aβ40 Transfection Aβ42 Aβ40 Ratio Mock (LacZ/empty 1.0 1.0 1.0 vector) wild type PAMP 1.03 ± 0.09 1.05 ± 0.07 0.99 ± 0.07 D336A/Y337A 3.09 ± 0.59 1.61 ± 0.19 1.81 ± 0.15 (p < 0.001) (p = 0.001) (p < 0.001) PAMPΔ312-369 0.05 ± 0.04 0.31 ± 0.06 0.09 ± 0.05 (p < 0.001) (p < 0.001) (p < 0.001) PAMPΔ312-340 0.33 ± 0.04 0.55 ± 0.04 0.59 ± 0.06 (p = 0.002) (p = 0.001) (p = 0.003) - PAMP interaction with Notch was studied using a Notch-cleavage assay (De Strooper, 1999). Notch cDNA was tagged with myc to the membrane-portion of Notch or to the soluble proteolytic derivative called Notch intra-cellular domain (NICD). V5-epitope-tagged PAMP and myc-tagged-Notch cDNAs were co-transfected into HEK293 cells. Thereafter, V5-tagged-PAMP was immunoprecipitated with anti-V5-antibodies, and the immunoprecipitation products investigated for myc-tagged proteins. In the immunoprecipitate, myc-tagged-Notch was found, but not myc-tagged-NICD. This result indicates a specific interaction between PAMP and the Notch precursor (which is the expected substrate for presenilin-dependent S3 cleavage). In contrast, PAMP did not bind to NICD, which arises as a product of presenilin-PAMP-mediated S3 cleavage of the Notch precursor.
- A study is conducted to investigate PAMP sequence, its expression levels, and its activity, in selected study objects. Initially, the study objects are selected from families having (1) increased rates of schizophrenia, and (2) a high proportion linked to the susceptibility locus on
chromosome 1 q21-q22 as described in Brzustowicz et al., 2000. Control individuals are selected from families with no or only a rare occurrence of schizophrenia. - Tissue samples are collected from study objects and control objects. The samples can be obtained either by sampling tissue fluids such as blood and cerebrospinal fluid, or by taking biopsies from selected tissues. In certain instances it may be preferable to collect tissue biopsies, e.g. from brain, kidney, or lung, from deceased study or control objects, i.e. post-mortem.
- The samples are analyzed for at least one of the following: (1) sequence of the entire or selected portions of the PAMP gene; (2) sequence and levels of PAMP mRNA; (3) sequence, levels, and activity of PAMP protein; (4) levels of a PAMP substrate. Identification of relevant mutations in the PAMP gene or mRNA is performed by using PCR together with primers specific for PAMP DNA or mRNA and radiolabeled nucleotides, hybridization analysis, and/or other automated sequencing techniques described herein or in references provided in the present disclosure, which are all incorporated by reference. Mutations in and levels of the PAMP protein is studied by, e.g., purifying PAMP from the tissue sample, performing enzyme-linked immunosorbent assay (ELISA) or other quantitative or semi-quantitative immunoassays, Edman degradation analysis, mass-spectroscopy, Western blotting, or other analytical techniques described herein or in references in the present disclosure. PAMP biological activity assays are conducted as described herein by either in vivo methods (e.g., monitoring βAPP processing and the production of amyloid-β peptide (Aβ), or other suitable protein substrates for PAMP including Notch, etc.), or by in vitro assays (using either whole cell or cell-free assays to measure processing of suitable substrates including βAPP or parts thereof, and other proteins such as Notch).
- The results from these assays will preferably show any significant correlation between mutations in and/or expression levels of PAMP or the PAMP gene and susceptibility to schizophrenia. PAMP or PAMP mutations, or altered PAMP or PAMP levels, identified in this manner can advantageously be used in the creation of in vivo assays (e.g., transgenic animals) or in vitro assays to study induction and/or progression of schizophrenia, as well as in the screening of potential therapeutic agents for schizophrenia. For instance, in an in vivo transgenic/recombinant mouse model, partial phenotypes could be examined via behavioral deficits in, e.g., exploratory behavior, novelty seeking, cognitive flexibility/rigidity, sensitivity to dopamine-induced motor disturbances, etc. (see Cloninger et al., 1996).
- The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
- It is further to be understood that values are approximate, and are provided for description.
- Patents, patent applications, and publications are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purposes.
-
- Altschul et al., J Mol Biol 1990; 215: 403-410.
- Araki et al., Nucleic Acids Res 1997; 25:868 et seq.
- Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc., 1994.
- Baker, Bioessays 2000; 22:264-273.
- Beard et al., Virology 1990; 75:81 et seq.
- Bender et al., J. Virol. 1987; 61:1639 et seq.
- Bernstein et al. Genet. Eng. 1985; 7:235 et seq.
- Borchelt et al., Neuron 1996; 17:1005-1013
- Brzustowicz et al., Science 2000; 288:678-682.
- Buxbaum et al., Proc. Natl. Acad. Sci. USA 1990; 87: 6003-6007
- Chen, Mol. Med. Today, 1997; 3:160-167
- Citron et al., Nature Med. 1997; 3:67-72
- Cloninger et al., Nature Genet. 1996; 12:3-4.
- Coffman, Semin. Nephrol. 1997; 17:404 et seq.
- Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985.
- Cote et al., Proc. Natl. Acad. Sci. U.S.A. 1983; 80:2026-2030.
- Curiel et al., Hum. Gene Ther. 1992; 3:147-154.
- Cwirla, et al., Proc. Natl. Acad. Sci., 1990; 87:6378-6382.
- De Strooper et al., Nature 1999; 398:518-522
- De Strooper et al., J. Biol. Chem. 1997; 272:3590-3598
- De Strooper et al., Nature 1998; 391:387-390.
- Devlin et al., Science, 1990; 49:404-406.
- Doan et al., Neuron 1996, 17:1023-1030
- Duff et al., Nature 1996; 383:710-713
- Elefanty et al., Proc Natl Acad Sci USA 1998; 95:11897, 1998.
- Esther et al., Lab. Invest. 1996; 74:953 et seq.
- Falkai et al., Biol Psychiatry 2000; 47:937-943.
- Feigner and Ringold, Science 1989; 337:387-388.
- Felgner, et. al., Proc. Natl. Acad. Sci. U.S.A. 1987; 84:7413-7417.
- Figeys et al., Anal Chem 1999; 71: 2279-2287.
- Flaum et al., In: Widiger et al. (eds.): DSM-IV Sourcebook, Vol. 4. Washington, D.C.: American Psychiatric Association, 1997.
- Fodor et al., Science 1991; 251:767-773
- Freshney R I (ed), Animal Cell Culture, 1986.
- Furka et al., 14th Int. Congress of Biochemistry, 1988; 5:Abstract FR:013.
- Furka, Int. J. Peptide Protein Res. 1991; 37:487-493
- Geysen et al., J. Immunologic Method 1987; 102:259-274.
- Geysen et al., Molecular Immunology 1986; 23:709-715.
- Gillman et al., Gene 1979; 8:81-97.
- Glover (ed.), DNA Cloning: A Practical Approach, Volumes I and II, 1985.
- Goate et al., Nature 1991; 349:704-706.
- Graham et al., J. Gen. Virol. 1977; 36:59 et seq.
- Graham, EMBO J. 1984; 3:2917 et seq.
- Greene N D, et al., Mech Dev 1998; 73: 59-72.
- Greenwald, et al., Cell 1983: 34; 435-444.
- Greenwald and Seydoux, Nature 1990: 346:197-199.
- Haass and Selkoe, Nature 1998; 391:387-390
- Hames & Higgins (eds.), Transcription And Translation, 1984.
- Hames & Higgins (eds.), Nucleic Acid Hybridization, 1985.
- Handler et al., Development 2000 June; 127(12):2593-606.
- Hartmann et al., Curr Biol 1999; 15:719-727.
- Huse et al., Science 246:1275-1281, 1989
- Immobilized Cells And Enzymes, JRL Press, 1986
- Indolfi et al., Nat. Med., 1996; 2:634-635
- Innis (ed.), PCR Protocols: A Guide to Methods and Applications, Academic Press, New York, 1990.
- Jones et al., Nature Genet. 1992; 1:306-309.
- Kafri, et al., J. Virol., 1999; 73: 576-584.
- Kaplitt et al., Mol. Cell. Neurosci. 1991; 2:320-330.
- Kehoe P, et al. Hum Mol Genet. 1999; 8: 237-245.
- Kijima et al., Pharmacol. Ther. 1995; 68:247-267.
- Köhler and Milstein, Nature 1975; 256:495-497.
- Kozbor et al., Immunology Today 1983; 4:72 et seq.
- Kuo et al., Blood 1993; 82:845 et seq.
- Lehmann et al., J. Biol. Chem. 1997; 272:12047-12051
- Levesque et al., J Neurochem 1998: 72:999-1008
- Levitan et al., Nature 1995; 377:351-354
- Levrero et al., Gene 1991; 101:195 et seq.
- Levy-Lahad et al, Science 1995; 269:970-973
- Li et al., Cell 1997; 90:917-927
- M. J. Gait (ed.), Oligonucleotide Synthesis, 1984.
- Mackey, et al., Proc. Natl. Acad. Sci. U.S.A. 1988; 85:8027-8031.
- Main et al., 1983, Cell 1983; 33:153 et seq.
- Margalit, et al., J. Immunol., 1987; 138:2213 et seq.
- Markowitz et al., 1988, J. Virol. 1988; 62:1120 et seq.
- Martin et al., NeuroReport 1995; 7:217-220
- McCormick, BioTechnology 1985; 3:689 et seq.
- Mir et al., C.P. Acad. Sci., 1998; 321:893 et seq.
- Morrison et al., J. Bacteriol. 1984; 159:870 et seq.
- Murakami et al., Blood Press. 1996; 2(Suppl.):36 et seq.
- Naldini, Curr. Opin. Biotechnol., 1998; 9:457-63.
- Needels et al., Proc. Natl. Acad. Sci. USA 1993; 90:10700-4.
- Neuberger et al., Nature 1984; 312:604-608.
- Nielsen et al., Science 1991; 254:1497 et seq.
- Nishimura M, et al., Nature Med 1999; 5: 164-169.
- Ohlmeyer et al., Proc. Natl. Acad. Sci. USA 1993; 90: 10922-10926.
- Paffenholtz et al., Exp Cell Res 1999; 250:452-464
- Paffenholtz et al., Differentiation 1997; 61:293-304
- Perbal, A Practical Guide To Molecular Cloning, 1984
- Reeck et al., Cell 50:667, 1987.
- Roberts et al. Nature 1987; 328:731-734.
- Roemer et al., New Biol. 3:331, 1991.
- Rogaev et al., Nature 1995; 376:775-778
- Rothbard, Ann. Inst. Pateur., 1986; 137E:518 et seq.
- Rothbard and Taylor, EMBO J. 1988; 7:93 et seq.
- Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.
- Scheuner et al., Nature Med. 1996; 2:864-870.
- Scheuner D, et al. Nature Med 1996; 2: 864-870.
- Scott and Smith, Science 1990; 249:386-390.
- Seeger et al., Proc. Natl. Acad. Sci. 1997; 94: 5090-5094.
- Selkoe, Curr Opin Neurobiol 2000; 10:50-57.
- Shen J, et al., Cell 1997; 89: 629-639.
- Sherrington et al., Nature 1995; 375:754-760
- Song et al., Proc Natl Acad Sci USA 1999; 96:6959-6963
- Spitz et al., Anticancer Res. 1996; 16:3415-3422
- Spouge et al., J. Immunol. 1987; 138:2204 et seq.
- Stefan and Murray, Acta Pædiatrica Suppl. 1997; 422: 112-116.
- Struhl and Greenwald, Nature 1999; 398:522-525
- Takeda et al., Nature 1985; 314:452-454.
- Ulmer et al., Science 1993; 259:1745-1748.
- Underhill D A, et al., Genomics 1999; 55: 185-193
- Walter et al., Molec. Medicine 1996; 2:673-691.
- Wei and Hemmings, Nature Genet. 2000; 25:376-377.
- Westphal and Leder, Curr Biol 1997; 7:530 et seq.
- Williams et al., Proc. Natl. Acad. Sci. USA 1991; 88:2726-2730.
- Wilson et al., Nature 1994; 368:32-38.
- Wilson and Kay, Nat. Med. 1995 September; 1(9):887-9.
- Wolfe M S, et al., Nature 1999; 398: 513-517
- Wolozin et al., Science 1996; 274:1710-1713
- Wong P C, et al., Nature 1997; 387:288-292.
- Wu et al., J. Biol. Chem. 1992; 267:963-967.
- Wu and Wu, J. Biol. Chem. 1987; 262:4429-4432.
- Wu and Wu, J. Biol. Chem. 1988; 263:14621-14624.
- Ye et al., Nature 1999; 398:525-529.
- Yu et al., Biol Chem 1998; 273:16470-16475
- Yu et al., Nature, in press, 2000.
- Zhang L, et al., J Biol Chem 1999; 274: 8966-8972
- Zhang and Henderson, Biotechniques 1998; 25:784 et seq.
- Zhou, et al., Genes and Development 1995; 9:2623-34.
- Zhou et al. (1), Neuro. Report (Fast Track) 1997; 8:1025-1029.
- Zhou et al. (2), Neuroreport 1997; 8:2085-2090.
- Zufferey, et al., J. Virol., 1998; 72:9873-80.
Patent Literature: - Canadian Patent Application No. 2,012,311
- European Patent Publication No. EP 453242
- European Patent Publication No. EP 488528
- European Patent Publication No. EP178220
- European Patent Publication No. EP 185 573
- International Patent Publication No. WO 96/34099
- International Patent Publication No. WO 95/02697
- International Patent Application No. WO 95/22617
- International Patent Publication No. WO 96/22378
- International Patent Application No. WO 91/09967
- International Patent Publication No. WO 89/12690
- International Patent Publication No. WO95/02697
- International Patent Publication No. WO94/12649
- International Patent Publication No. WO 91/18088
- International Patent Publication No. WO94/28152
- International Patent Application No. WO94/26914
- International Patent Publication No. WO 92/00252
- International Patent Publication No. WO94/28938
- International Patent Publication No. WO 9428028
- International Patent Publication No. WO 99/01175
- International Patent Publication No. WO 99/01158
- International Patent Publication No. WO 99/01157
- International Patent Publication No. WO 95/07358
- International Patent Application No. WO 95/28494
- International Patent Publication No. WO 93/09239
- International Patent Publication No. WO95/21931
- International Patent Publication No. WO96/25508
- International Patent Publication No. WO95/21931
- International Patent Publication No. WO96/17823
- International Patent Publication No. WO95/18863
- International Patent Publication No. WO94/26914
- International Patent Application No. WO 90/02806
- International Patent Publication No. WO 94/21807
- International Patent Application No. WO 89/07150
- International Patent Application No. WO 96/39036
- International Patent Application No. WO 97/19182
- International Patent Publication No. WO 92/05263
- International Patent Application No. WO 95/26411
- U.S. Pat. No. 5,986,054
- U.S. Pat. No. 5,040,540
- U.S. Pat. No. 6,020,143
- U.S. Pat. No. 5,654,168
- U.S. Pat. No. 5,124,263
- U.S. Pat. No. 5,010,175
- U.S. Pat. No. 4,631,211
- U.S. Pat. No. 4,980,289
- U.S. Pat. No. 4,959,317
- U.S. Pat. No. 4,946,778
- U.S. Pat. No. 5,132,405
- U.S. Pat. No. 5,777,195
- U.S. Pat. No. 5,476,786
- U.S. Pat. No. 4,650,764
- U.S. Pat. No. 5,399,346
- U.S. Pat. No. 5,225,539
- U.S. Pat. No. 5,801,030
- U.S. Pat. No. 5,693,762
- U.S. Pat. No. 5,693,761
- U.S. Pat. No. 5,139,941
- U.S. Pat. No. 5,585,089
- U.S. Pat. No. 4,797,368
- U.S. Pat. No. 5,616,491
- U.S. Pat. No. 4,861,719
- U.S. Pat. No. 5,459,127.
- U.S. Pat. No. 5,792,844
- U.S. Pat. No. 5,814,500
- U.S. Pat. No. 5,811,234
- U.S. Pat. No. 5,780,607
- U.S. Pat. No. 5,677,437
- U.S. Pat. No. 5,034,506
- U.S. Pat. No. 5,783,682
- U.S. Pat. No. 5,580,859
- U.S. Pat. No. 5,589,466
- U.S. Pat. No. 5,637,684
Claims (16)
1. A method for detecting a mutation in presenilin associated membrane protein (AMP) associated with a neuropsychiatric or neurodevelopmental disorder, which method comprises detecting a variation in a sequence of a gene encoding PAMP obtained from an individual diagnosed with or suspected of having said disorder.
2. The method of claim 1 , wherein the disorder is schizophrenia.
3. A method for diagnosing individuals predisposed to or having a neuropsychiatric or neurodevelopmental disorder, which method comprises detecting a mutation in a gene encoding PAMP obtained from an individual.
4. The method of claim 3 , wherein the disorder is schizophrenia.
5. The method according to claim 3 , wherein detection of the mutation comprises measuring a level of transcriptional activity of the gene.
6. The method according to claim 3 , wherein detection of the mutation comprises measuring PAMP activity.
7. The method of claim 6 , wherein said PAMP activity comprises PAMP expression level or activity of a product of a PAMP modified substrate.
8. A method for identifying a compound that is useful in treating a neuropsychiatric or neurodevelopmental disorder, which method comprises detecting modulation of PAMP expression in a transgenic animal that expresses PAMP, wherein the animal is contacted with the compound.
9. The method of claim 8 , wherein the disorder is schizophrenia.
10. A method for identifying a compound that is useful in treating a neuropsychiatric or neurodevelopmental disorder, which method comprises:
(a) contacting a reconstituted system for measuring presenilin associated membrane protein (AMP) activity, comprising PAMP, or a functional fragment thereof, and a PAMP substrate, with a test compound; and
(b) detecting a difference in PAMP activity in the presence of the compound compared to the PAMP activity in the absence of the compound.
11. The method of claim 10 , wherein the disorder is schizophrenia.
12. A method for identifying a compound that is useful in treating a neuropsychiatric or neurodevelopmental disorder, which method comprises:
(a) contacting a complex between a presenilin associated membrane protein (PAMP) and an agent, which agent provides a detectable conformational or functional change in said PAMP upon interaction with a substance being analyzed for activity against a neurodegenerative disease, with a test compound; and
(b) detecting a conformational or functional change in PAMP in the complex.
13. The method of claim 12 , wherein the disorder is schizophrenia.
14. The method of claim 12 , wherein the test compound is a protein that interacts with PAMP.
15. A method for treating neuropsychiatric or neurodevelopmental disorder in a mammalian host which expresses at least one PAMP protein or a naturally occurring variant, which method comprises administering to the host an amount of compound effective to modulate PAMP expression in the host.
16. The method of claim 15 , wherein the disorder is schizophrenia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/893,494 US20080064638A1 (en) | 2000-09-01 | 2007-08-15 | Proteins related to schizophrenia and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22988900P | 2000-09-01 | 2000-09-01 | |
US09/945,258 US6929919B2 (en) | 2000-09-01 | 2001-08-31 | Proteins related to schizophrenia and uses thereof |
US11/170,482 US20060094037A1 (en) | 2000-09-01 | 2005-06-28 | Proteins related to schizophrenia and uses thereof |
US11/893,494 US20080064638A1 (en) | 2000-09-01 | 2007-08-15 | Proteins related to schizophrenia and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/170,482 Continuation US20060094037A1 (en) | 2000-09-01 | 2005-06-28 | Proteins related to schizophrenia and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080064638A1 true US20080064638A1 (en) | 2008-03-13 |
Family
ID=22863072
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/945,258 Expired - Fee Related US6929919B2 (en) | 2000-09-01 | 2001-08-31 | Proteins related to schizophrenia and uses thereof |
US11/170,482 Abandoned US20060094037A1 (en) | 2000-09-01 | 2005-06-28 | Proteins related to schizophrenia and uses thereof |
US11/893,494 Abandoned US20080064638A1 (en) | 2000-09-01 | 2007-08-15 | Proteins related to schizophrenia and uses thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/945,258 Expired - Fee Related US6929919B2 (en) | 2000-09-01 | 2001-08-31 | Proteins related to schizophrenia and uses thereof |
US11/170,482 Abandoned US20060094037A1 (en) | 2000-09-01 | 2005-06-28 | Proteins related to schizophrenia and uses thereof |
Country Status (4)
Country | Link |
---|---|
US (3) | US6929919B2 (en) |
AU (1) | AU2001287448A1 (en) |
CA (1) | CA2417136A1 (en) |
WO (1) | WO2002018434A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080075789A1 (en) * | 2006-02-28 | 2008-03-27 | The Regents Of The University Of California | Genes differentially expressed in bipolar disorder and/or schizophrenia |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
US20030175287A1 (en) * | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
AU2002361682A1 (en) * | 2001-12-14 | 2003-06-30 | Elizabeth Kopp | Innate immune system-directed vaccines |
WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
MX2011005963A (en) * | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugates of neurotensin or neurotensin analogs and uses thereof. |
US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US6020143A (en) * | 1996-01-26 | 2000-02-01 | Research And Development Limited Partnership | Method for identifying substances that affect the interaction of a presenilin-1-interacting protein with a mammalian presenilin-1 protein |
US6383758B1 (en) * | 1998-01-09 | 2002-05-07 | The Governing Council Of The University Of Toronto | Alzheimer's related proteins and methods of use |
US6812337B1 (en) * | 1999-04-01 | 2004-11-02 | The Governing Council Of The University Of Toronto | Presenilin associated membrane protein and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3650600A (en) | 1999-04-01 | 2000-10-23 | Governing Council Of The University Of Toronto, The | A presenilin associated membrane protein and uses thereof |
EP1242443A4 (en) | 1999-12-23 | 2005-06-22 | Nuvelo Inc | Novel nucleic acids and polypeptides |
GB0005894D0 (en) | 2000-03-10 | 2000-05-03 | Glaxo Group Ltd | Assay |
-
2001
- 2001-08-31 US US09/945,258 patent/US6929919B2/en not_active Expired - Fee Related
- 2001-08-31 CA CA002417136A patent/CA2417136A1/en not_active Abandoned
- 2001-08-31 WO PCT/CA2001/001243 patent/WO2002018434A2/en active Application Filing
- 2001-08-31 AU AU2001287448A patent/AU2001287448A1/en not_active Abandoned
-
2005
- 2005-06-28 US US11/170,482 patent/US20060094037A1/en not_active Abandoned
-
2007
- 2007-08-15 US US11/893,494 patent/US20080064638A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US6020143A (en) * | 1996-01-26 | 2000-02-01 | Research And Development Limited Partnership | Method for identifying substances that affect the interaction of a presenilin-1-interacting protein with a mammalian presenilin-1 protein |
US6383758B1 (en) * | 1998-01-09 | 2002-05-07 | The Governing Council Of The University Of Toronto | Alzheimer's related proteins and methods of use |
US6812337B1 (en) * | 1999-04-01 | 2004-11-02 | The Governing Council Of The University Of Toronto | Presenilin associated membrane protein and uses thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080075789A1 (en) * | 2006-02-28 | 2008-03-27 | The Regents Of The University Of California | Genes differentially expressed in bipolar disorder and/or schizophrenia |
Also Published As
Publication number | Publication date |
---|---|
US6929919B2 (en) | 2005-08-16 |
AU2001287448A1 (en) | 2002-03-13 |
US20060094037A1 (en) | 2006-05-04 |
CA2417136A1 (en) | 2002-03-07 |
WO2002018434A3 (en) | 2002-12-12 |
WO2002018434A2 (en) | 2002-03-07 |
US20020058276A1 (en) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8067224B2 (en) | Presenilin associated membrane protein (PAMP) and uses thereof | |
US5840540A (en) | Nucleic acids encoding presenilin II | |
JP2000506375A (en) | Nucleic acids and proteins associated with Alzheimer's disease and uses thereof | |
US20080064638A1 (en) | Proteins related to schizophrenia and uses thereof | |
EP1165779A1 (en) | A presenilin associated membrane protein and uses thereof | |
US7795394B2 (en) | Saitohin gene and uses of same | |
JP2000516087A (en) | Gene sequences and proteins associated with Alzheimer's disease and uses thereof | |
US7294710B2 (en) | High-affinity choline transporter | |
US6998467B1 (en) | Antibody specific for presenilin 1 and method of use thereof | |
US20040209310A1 (en) | Ligands that bind to the amyloid-beta precursor peptide and related molecules and uses thereof | |
AU2002359385A1 (en) | A novel saitohin gene and uses of same | |
JP2007532610A (en) | Diagnostic and therapeutic uses of KCNC1 for neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |